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 ABSTRACT 
 
Despite numerous options for treatment of rheumatic diseases, there is an unfulfilled 
clinical need for therapeutic strategies that can reduce inflammation and prevent tissue 
destruction. Lipid mediators (eicosanoids and fatty acids (FA)) are involved in the 
regulation of inflammatory processes and contribute to the pathogenesis of rheumatic 
diseases. Thus, selective targeting of the lipid mediators might enable improved anti-
inflammatory treatment. Microsomal prostaglandin synthase (mPGES) -1 produces 
prostaglandin E2 (PGE2) at sites of inflammation in rheumatic diseases. Inhibitors of 
mPGES-1 have been proposed as a more selective anti-inflammatory treatment retaining 
the therapeutic potential of non-steroidal anti-inflammatory drugs (NSAIDs) but with less 
severe side effects associated with NSAIDs. However, the impact of mPGES-1 inhibition 
on different pathological and physiological processes is not completely elucidated. 
Moreover, chronic inflammation might cause dysregulation of lipid and FA metabolism 
that may contribute to skeletal muscle weakness in patients with polymyositis (PM) and 
dermatomyositis (DM).  
The major aim of this thesis was to gain better understanding of the regulation of PGE2 and 
other lipid mediators in RA, PM and in DM to improve treatment of patients. 
 
First, we have determined the catalytic mechanism of mPGES-1 activity by site-directed 
mutagenesis (Paper I). The amino acid residues arginine (Arg) 126 and aspartate (Asp) 49 
were identified as essential for the catalytic activity of mPGES-1, as when exchanged, the 
enzyme variants lost their enzymatic activity. Previous high-resolution structural studies 
predicted a role for serine (Ser) 127 in the enzymatic activity of mPGES-1. In contrast, we 
have demonstrated that Ser127, as well as Arg73, do not seem to be significant to the 
catalytic mechanism because when exchanged, their variants retained considerable activity. 
These results are of relevance for the development of the new generation of mPGES-1 
inhibitors. 
 
Further, we studied whether mPGES-1 deletion might be beneficial for reducing 
inflammation via the suppression of platelet functions (Paper II). Platelet activation, the 
formation of platelet-leukocyte aggregates, and release of platelet-derived microparticles 
(PMP) were significantly reduced in mPGES-1 KO mice compared to WT after 
lipopolysaccharide (LPS) treatment. In addition, KO mice displayed a significant decrease 
in platelet aggregation ex vivo. The reduced activation of platelets may contribute to anti-
inflammatory effect and cardiovascular safety of mPGES-1 inhibitors.  
 
In Paper III, we investigated effects of mPGES-1, PGIS, and cyclooxygenase (COX) -2 on 
vascular and renal pathways associated with asymmetric dimethylarginine (ADMA) and 
endothelial nitric oxide synthase (eNOS). WT mice treated with COX-2 inhibitor displayed 
no change in the plasma levels of cardioprotective prostacyclin (PGI2), while mPGES-1 KO 
mice showed significantly higher PGI2 levels in the plasma. In contrast to COX-2 
inhibition, mPGES-1 deletion had no effect on genes responsible for the production or 
breakdown of ADMA in the kidney. Plasma creatinine and ADMA were elevated in mice 
 treated with COX-2 inhibitor or PGIS KO mice but unaltered in mPGES-1 KO mice. 
Furthermore, the deletion of mPGES-1 significantly improved the eNOS-driven dilator 
response to acetylcholine in the aorta. These data further confirmed the cardioprotective 
effects of mPGES-1 deletion suggesting selective inhibitors of mPGES-1 as a safer 
alternative to NSAIDs.  
 
To clarify mechanisms involved in muscle weakness, we examined effects of the 
conventional immunosuppressive treatment on global gene expression profiles in skeletal 
muscle from PM and DM patients (Paper IV). The genes related to immune response and 
inflammation including the interferon and the inflammasome pathways were downregulated 
by treatment. The genes involved in muscle tissue remodeling and growth were negatively 
affected by treatment. The immunosuppressive treatment caused an induction of gene 
markers of fast type II fibers. Furthermore, the fiber composition of the muscle tissue from 
patients was switched towards type II fibers after treatment. Importantly, the expression of 
genes involved in lipid metabolism was altered, signifying a probable lipotoxic effect on 
muscles, that at least partly might explain the persistent muscle weakness and fatigue 
observed in PM and DM patients despite treatment.  
 
To confirm dysregulated lipid metabolism in myositis patients, we analyzed lipid and FA 
profiles in serum from patients with PM and DM in comparison to healthy individuals and 
response to immunosuppressive treatment (Paper V). FA composition of total serum lipids 
was changed in myositis patients compared to healthy individuals. In myositis patients, the 
levels of palmitic 16:0 acid was significantly higher while the levels of arachidonic 20:4(n-
6) acid was significantly lower. The levels of serum lipid species within 
phosphatidylcholine (PC), lysophosphatidylcholine (LPC) and triglycerides (TG) were also 
significantly changed in myositis patients compared to healthy individuals. 
Immunosuppressive treatment resulted in increased serum levels of C20:2(n-6) acid and 
C20:5(n-3) acids as well as in the changed serum PC, phosphatidylethanolamine (PE) and 
LPC profiles in myositis patients.   
 
In conclusion, in this thesis, we have provided new knowledge on the catalytic mechanism 
and the impact of mPGES-1 on inflammation and cardiovascular safety. Furthermore, we 
have demonstrated that lipid metabolism is altered in PM and DM patients and might 
contribute to disease pathogenesis. 
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 1 
INTRODUCTION  
The immune system is one of the most vital systems in the human body; it has evolved to 
protect our bodies against foreign threats such as microbes, viruses, and parasites. During 
normal condition, the system is in homeostasis, but during the invasion by foreign 
pathogens, an orchestra of cells and molecules acting via different mechanisms defends the 
body from the external threat. The inbuilt capacity of the system is to avoid self-damaging, 
but occasionally, the reason(s) being mostly unknown, the immune reactions against “self” 
or molecules that become auto-antigenic arise and cause chronic inflammation leading to 
autoimmune diseases. Approximately ~5% of the world’s population suffers from 
autoimmune disorders, causing severe disability as well as a heavy economic burden to the 
society (1, 2). In chronic and destructive autoimmune disorders, such as rheumatoid 
arthritis (RA) and idiopathic inflammatory myopathies (IIM), inflammation and pain are 
common symptoms. 
 
The anti-rheumatic treatment is often insufficient despite a wide selection of available 
drugs, more worrisome, many patients remain disabled. Therefore, there is a great need for 
selective and improved anti-inflammatory treatments. Lipid mediators such as eicosanoids 
and fatty acids (FA) are important regulators of inflammatory processes and contribute to 
the pathogenesis of rheumatic diseases. Thus, selective targeting of the lipid mediators 
might enable improved anti-inflammatory treatment.  
 
Prostaglandin E2 (PGE2) is an essential lipid mediator of inflammation and pain that is 
deeply involved in the pathogenesis of RA and myositis. Non-steroidal anti-inflammatory 
drugs (NSAIDs), inhibiting cyclooxygenase (COX) activity, are the first line drugs for the 
treatment of inflammation and pain. However, due to inhibition of all downstream 
prostaglandins, including the ones with housekeeping functions, treatment with NSAIDs is 
associated with several severe side effects such as gastric ulcers and cardiovascular 
complications.  
Hence, microsomal prostaglandin E2 synthase (mPGES)-1 acting downstream of COX has 
been extensively investigated as a pharmaceutical target for anti-inflammatory treatment 
because of the advantage of selective inhibition of PGE2 (3, 4). 
Moreover, chronic inflammation might cause dysregulation of lipid and FA metabolism 
that may contribute to skeletal muscle weakness in patients with polymyositis (PM) and 
dermatomyositis (DM).  
 
This Ph.D. thesis intends to provide novel knowledge on the role of PGE2 and other lipid 
mediators in RA and PM/DM in order to improve treatment of patients. 
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Chronic inflammatory diseases  
This section will focus on chronic autoimmune diseases and therapeutic strategies.  
 
 
Inflammation 
 
Every surface and every cavity of the human body is coated with a barrier, physical and 
chemical, to protect against foreign invaders and maintain homeostasis. In the event of the 
barrier breach or tissue injury, activation of danger-sensing mechanisms occurs, initiating 
the inflammatory and immune reactions in the attempt to fight the foreign invader and 
regain tissue homeostasis.  
 
Symptoms of inflammation are classically described as pain, redness, swelling and heat. 
The pain alerts the host of the abnormal state of the target tissue. Redness, swelling, and 
heat are due to the increased blood flow and consequently plasma leakage. During normal 
conditions, the orchestra of molecules causing the inflammation regains the balance and a 
state of homeostasis restores. But, when the balance is dysregulated the inflammation 
amplifies causing irreversible loss of function of the afflicted organ (5).  
 
Inflammation is defined as a response with the purpose to create a hostile environment for 
the invading pathogen to be overpowered as well as to repair the damaged tissue. The 
inflammatory response is orchestrated by cells of the targeted organ as well as the immune 
cells brought via the increased blood flow. The cross-talk between these cells occurs via 
mediators such as cytokines, chemokines, and lipid mediators; facilitating differentiation 
and modulation of cells of the immune system. Another very important role these mediators 
play is the recruitment of inflammatory cells to the afflicted organ. An essential family of 
mediators in this network is eicosanoids, which modulate inflammation (5, 6). This section 
will focus on inflammatory disorders such as rheumatoid arthritis (RA) and idiopathic 
inflammatory myopathies (IIM) and therapeutic strategies for these autoimmune diseases.  
 
 
Rheumatoid arthritis (RA) 
 
RA is a chronic autoimmune inflammatory disorder with an overall prevalence of 0.5-1% in 
western countries, with a higher prevalence (3:1) in females and an incidence of 2-50/100 
000/per year (7). The disease is more predominant in North America and North Europe and 
is portrayed by persistent inflammation in the synovial joints causing major damage and 
pain. RA is characterized by joint swelling, pain, cartilage and bone erosions, ultimately 
leading to severe and permanent disability, although not all RA patients show signs of bone 
erosions. Small and medium-size joints are usually symmetrically affected (7). RA is 
associated with several co-morbidities such as higher risk of cancer mainly lymphomas, 
cardiovascular disease and interstitial lung disease (ILD) (7, 8).  
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The etiology of RA is still enigmatic; however, compelling evidence suggests that an 
interaction between the environmental and genetic factors triggers the onset of the disease 
(9, 10). Data from twin studies revealed a 15% increase in RA prevalence in twins, showing 
a clear impact of the interaction between the environmental and the genetic factors on RA 
risk (11, 12) 
 
Pain is the most common symptom that patients complain about (13). Similar to the 
immune response, pain naturally exerts an essential protective role in the body. However, 
every so often patients with RA develop chronic pain. Despite treatment with NSAIDs, 
disease modifying anti-rheumatic drugs (DMARDs) and biologics, the pain often persists 
while the joint inflammation and the overall disease activity decreases as well as when the 
patient is in remission (14). In many cases, patients develop arthralgia before synovitis 
which is a predictive element in the development of RA (15).  
 
 
 
Idiopathic inflammatory myopathies (IIM)  
 
Clinical features of chronic inflammatory diseases such as autoimmune myopathies, 
including polymyositis (PM) and dermatomyositis (DM) are muscle atrophy and weakness. 
Common histopathological features of PM and DM are muscle fiber degeneration and 
regeneration, also the presence of inflammatory cells in skeletal muscle tissue (16). Both 
immune and non-immune mechanisms are associated with the pathogenesis of the disease 
(17). Immune mechanisms contributing to the disease include the presence of 
autoantibodies, infiltrating T cells, macrophages and dendritic cells in muscles as well as 
elevated expression of MHC class I molecule in muscle fibers. Furthermore, the production 
of pro-inflammatory cytokines e.g. interleukin (IL) -1β and type 1 interferons (IFNs) (18, 
19) as well as the expression of enzymes involved in the production of prostaglandins and 
leukotrienes are elevated in muscle tissues from myositis patients (20, 21).  
 
Non-immune mechanisms implicated in muscle weakness in patients suffering from PM or 
DM are endoplasmic reticulum stress and capillary-loss-induced hypoxia (16, 22). 
However, the precise role of the immune and non-immune mechanisms in causing muscle 
weakness still needs to be clarified. Moreover, the lack of correlation between 
inflammation and muscle weakness is not well understood (17).  
 
 
 
Therapeutic strategies in RA and IIM 
 
There are numerous treatment options for rheumatic patients, but despite extensive 
therapeutic developments none has been proven to act as a cure for the diseases. 
Accumulated scientific evidence suggests that the earlier the treatment begins, the earlier 
the activity of the disease is reduced leading to a better outcome for the patient.  
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Non-steroidal anti-inflammatory drugs (NSAIDs) 
 
Rheumatic patients exhibiting inflammation and pain are traditionally given NSAIDs which 
target COX enzymes by inhibiting the enzyme function of COX-1 and COX-2. NSAIDs 
reduce pain and inflammation and further improve the joint mobility in rheumatic patients, 
however, in opposite to the situation in ankylosing spondylitis there is no evidence 
demonstrating that NSAIDs are slowing the RA disease progression. Therefore, they are 
prescribed as an adjuvant treatment along with more potent anti-rheumatic medications 
such as synthetic or biological disease-modifying drugs.  
NSAIDs are associated with several side effects; common effects are nausea, vomiting, 
diarrhea, rash, dizziness and several others. However, there are several severe side effects 
associated with prolonged usage of NSAIDs including renal failure, gastrointestinal ulcers 
and bleedings as well as higher risk of cardiovascular events (23).   
 
NSAIDs cause side effects by interfering with homeostatic functions of prostanoids. 
Traditional NSAIDs are non-selective COX-1 and COX-2 inhibitors. During long-term use 
NSAIDs affect the housekeeping functions of COX-1-dervied prostaglandins in the 
stomach causing gastric ulcers (24). Coxibs is a family of selective COX-2 selective 
inhibitors, initially developed to inhibit the COX-2 isoform predominantly expressed 
during inflammation and spare physiological functions of COX-1. Moreover, Coxibs have 
beneficial effects in chemoprevention of colorectal cancer but are also associated with 
increased cardiovascular risks (25, 26) by interfering with the prostacyclin 
(PGI2)/thromboxane (TXA2) balance. Coxibs inhibit COX-2-mediated prostacyclin 
formation while allowing COX-1-mediated thromboxane synthesis, leading to platelet 
activation, increased thrombosis and myocardial infarction. 
 
Prostaglandins are also involved in the regulation of the water/salt balance of the body by 
causing vasodilation of the afferent arterioles of the glomeruli thus regulating the 
glomerular perfusion and glomerular filtration rate. Consequently, NSAIDs may cause 
afferent arterioles constriction and decreased renal perfusion pressure (27) leading to 
hypertonia. To dissociate the anti-inflammatory and pain killing effects of NSAIDs and 
Coxibs from their side effects, selective mPGES-1 inhibitors were suggested as an 
alternative anti-inflammatory treatment in chronic inflammatory diseases (28). 
 
 
Glucocorticoids (GC) 
 
Anti-inflammatory GC represent another important approach in treating rheumatic diseases 
such as RA and IIM. They are known to suppress disease activity and reduce inflammation, 
swelling and subsequently pain. Among other mechanisms, GC suppress cytosolic 
phospholipase A2 (cPLA2) and inhibits the expression of COX-2 and mPGES-1.  
 
 5 
Oral GC such as prednisolone are frequently used as a bridging therapy in combination 
with a DMARD initiation to control and regulate the disease activity until the time the 
DMARD treatment becomes clinically effective. Moreover, low-dose GC are regularly 
used supplementary to DMARDs for their joint-protective effects (29), although evidence 
point to a negative impact on bone mineral density with increased risk for bone fractures 
(30) as well as diabetes. Despite the negative impact on bone mineral density and risk of 
developing diabetes, low-dose GC in combination with anti-rheumatic treatment provide a 
better clinical outcome as well as less radiographic damages (31). There are few controlled 
trials in PM and DM regarding treatment with GC, and treatment recommendations are thus 
based mainly on clinical experience. Myositis patients are usually treated with high doses 
of GC, ranging from 0.75-1.00mg/kg per day, for several weeks and continuously for very 
long time on low-dose GC. Although many patients respond with improved muscle 
function, few patients recover previous muscle performance, and side effects are many (22).   
 
GC are lipid-soluble molecules and have anti-inflammatory effects mediated through 
several different mechanisms. Transactivation is a genomic mechanism, which is 
transcription dependent and activates gene transcription. GC passes freely through the cell 
membrane and binds to its ubiquitously expressed cytoplasmic GC-receptor (GR) that gets 
activated by ligand binding. The GC-receptor complexes are then translocated into the cell 
nucleus, where they bind to specific DNA sequences, so called GC response elements 
(GRE), in the promoter regions of GC-regulated genes and induce the transcription of target 
genes involved mainly in the resolution of inflammation, such as IL-10 and IL-1 receptor 
antagonist (32). The transactivation is thought to have a minor role in the anti-inflammatory 
effects of GC, it is believed to be associated with the many adverse effects of GC usage by 
augmenting the expression of genes involved in the different metabolic processes, leading 
to clinical manifestations like diabetes (33).  
 
Transrepression is another genomic mechanism, which is also transcription dependent but 
represses gene transcription. Here the activated GR-receptor complex prevents pro-
inflammatory transcription factors from binding their respective GRE (32). The GC-
receptor complex suppresses, therefore, the production of adhesion molecules, pro-
inflammatory cytokines, prostanoids and mediators mainly through interaction with other 
transcription factors such as Nuclear Factor-KB (NF-KB) and activator protein-1 (AP-1) 
(34).  
 
There is also non-genomic mechanism described for the actions of GC which is 
transcription independent and involves processes that do not directly influence the gene 
expression. It is characterized by rapid onset, within seconds to minutes, and short duration 
of action, 60-90 minutes, unlike the genomic actions which could take hours, however, its 
effects is dose-depended, similar to the genomic effects (35). Stahn et al., described three 
categories of the non-genomic actions of GC: nonspecific interactions of GC with cellular 
membranes, specific interactions of membrane-bound GR either with other proteins or 
mRNA (36) as well as non-genomic effects mediated through binding to the cytosolic GR 
(37).  
 6 
 
As with almost all drugs, long-term usage of GC is associated with several severe side 
effects including osteoporosis and diabetes (38). GC also have a direct catabolic effect on 
skeletal muscle as myopathy can be prevented by GR antagonist as has been shown in rats 
(39), moreover, GC interfere with insulin-like growth factor-1 (IGF-1) (40).  
 
 
Disease-modifying anti-rheumatic drugs (DMARDs) 
 
Rheumatic patients are often treated with DMARDs that affects disease progression by 
slowing down joint destruction and inflammation in skeletal muscle. DMARDs can be 
divided into two groups; synthetic molecules such as methotrexate and biological molecules 
such as TNF blockers.  
 
Methotrexate is the first-line choice therapy in RA and IIM treatment (41). The use of 
methotrexate as an adjunct treatment to oral GC following diagnose of RA and IIM is 
widely accepted. Evidence point to anti-inflammatory effects of low-dose methotrexate 
through several mechanisms including adenosine release, the suppression of T cell 
proliferation, increased apoptosis as well as modulation of cytokine production (42). 
Methotrexate interferes with DNA synthesis by inhibiting dihydrofolate reductase that 
forms tetrahydrofolate. This also leads to accumulation of adenosine monophosphate 
(AMP) and subsequently adenosine. Via these mechanisms, methotrexate, inhibits the 
proliferation of lymphocytes and the production of tumor necrosis factor (TNF)-α, IL-8, IL-
12 and IFN-γ (43).  
 
TNF blockers is a therapy used to treat RA and are known to set the disease to remission 
(44). Many patients on TNF blockers such as infliximab have fewer symptoms of 
inflammation, reduced disease activity and increased joint function (45). The most 
beneficial effects of TNF blockers are the prevention of cartilage and bone destruction (46). 
Biologicals are often used in combination with DMARDs, e.g. the use of TNF blockers is 
more efficient in combination with methotrexate when treating RA patients (46). TNF 
blockers inhibit leukocyte trafficking in the synovial compartment caused by the reduced 
levels of adhesion molecules, pro-inflammatory cytokines such as IL-6 and IL-8 and 
chemokines (47). Moreover, TNF blockers normalize the dysfunction of regulatory T cells 
by increasing their number and reversing their anergic phenotype (47). A recent study 
consisting of 99 patients with early untreated active RA was performed to investigate 
whether treatment with infliximab for six months in combination with methotrexate and 
prednisolone treatment gave a better 2-year outcome. Indeed, the combination treatment of 
patients resulted in clinical remission with less joint damage development as well as 
delaying the radiological progression (48).  
 
Other emerging pharmacological treatments targeting the Janus kinase (JAK) pathway 
include B cell depleting therapy (49), anti-IL-6, IL-1 and several others (50, 51).   
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Lipid mediators  
 
Lipid mediators are a large group of biologically active molecules that are locally generated 
via specific biochemical pathways in response to extracellular stimuli (52). They can be 
transported extracellularly, act on specific receptors and regulate essential cell functions. 
This section will focus on the following classes of lipid mediators: lysophospholipids 
(LPL), fatty acids (FA) and eicosanoids. 
 
 
 
Phospholipids (PL)  
 
PL are amphipathic molecules, meaning they have both hydrophilic (water-loving, polar) 
and lipophilic (fat-loving, apolar) properties. The PL molecule consists of a negatively 
charged hydrophilic head, phosphate group and two uncharged, hydrophobic tails also 
known as FA chains (53). These components are joined by a glycerol molecule, 
constructing the backbone of the PL molecule, and the phosphate group of a phospholipid is 
modified by alcohol (54, 55). The PL family includes phosphatidic acid (PA), 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) and 
phosphatidylinositol (PI). PL are essential components of cell membranes and critical for 
cell functions.  
 
 
Phosphatidic acid (PA) 
 
PA is a minor constitute of the cell membrane and influences the membrane curvature. PA 
can be synthetized de novo and is the precursor for the biosynthesis of other phospholipids. 
Furthermore, PA acts as a signaling lipid, recruiting cytosolic proteins to appropriate 
membranes. Moreover, PA is thought to induce mechanistic target of rapamycin (mTOR) 
signaling, a well-recognized pathway through which protein synthesis and muscle mass 
might be regulated by mechanical signals (56, 57). The main source of PA is soya- and egg-
based derivatives. A study with athletes given PA daily for 8 weeks demonstrated that the 
supplementation group gained in muscle strength and increased lean body mass (58). 
Moreover, PA supplementation is known to increase skeletal muscle hypertrophy and 
strength (59).  
 
 
Phosphatidylcholine (PC) 
 
PC is a class of phospholipids that contain choline as a headgroup. PC is a ubiquitous 
produced, one of the most abundant phospholipids present in the cell membrane and 
accounts for 50% of the phospholipids. PC is the main source of choline in the body, an 
essential nutrient, and precursor of the neurotransmitter, acetylcholine (60). PC is vital for 
the composition and repair of the cell membrane.  
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Phosphatidylethanolamine (PE) 
 
Another abundant phospholipid found in cell membranes is PE that account for 25% of all 
the phospholipids in cell membranes. PE are involved in fusion of membranes and 
regulation of membrane curvature as well as increasing viscosity of the membrane. PE are 
the main lipid component in the brain such as the white matter in the brain, nerves, spinal 
cord and neural tissue, where it accounts for 45% of all phospholipids (61).  
 
 
Phosphatidylserine (PS) 
 
As other phospholipids, PS is a component of the cell membrane and also play a vital role 
in cell signaling. During apoptosis, the PS is no longer restricted to the cytosolic side of the 
cellular membrane. Instead, it gets exposed on the extracellular surface,  acting as signaling 
molecules for macrophages to engulf the dying cell (62). Moreover, PS have also a role in 
blood coagulation, thus platelets activation by collagen and thrombin causes an 
externalization of PS from their inner membrane layer (63).  
 
 
Phosphatidylinositol (PI) 
 
PI is a phospholipid which plays an important role in cell signaling and membrane 
trafficking (64). The de novo biosynthesis of PI occurs in the endoplasmic reticulum (64). 
PI is especially abundant in brain tissue but is present in all tissues and cell types (64). 
Phosphoinositides are phosphorylated derivatives of PS and are known to be involved in 
regulating many cellular processes (65). PI is important for intracellular signaling and 
anchoring of carbohydrates and proteins to outer cellular membranes (66). 
 
 
 
Lysophospholipids (LPL) 
 
LPL are products of the hydrolysis of phospholipids in which one or two acyl chains are 
lacking. The best studied LPL include lysophosphatidic acid (LPA) and 
lysophosphatidylcholine (LPC). They are known to be important regulators of diverse 
physiological and pathophysiological functions such as reproduction, angiogenesis as well 
as inflammation and tumorigenesis (52, 67). LPL act via binding to their specific cognate 
receptors called lysophospholipids receptor (LPL-R), which are members of GPCR family. 
The effects of LPL highly depend on the length of the acyl chain and degree of saturation. 
LPL are present in numerous tissues and fluids both intracellularly and extracellularly (67). 
The central nervous system is one of the biological systems markedly affected by LPL 
signaling. 
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Lysophosphatidic acid (LPA) 
 
LPA is the major LPL formed and is an autocrine and/or paracrine bioactive signaling 
molecule, acting via different G-protein coupled LPA receptors, triggering a comprehensive 
series of intracellular signaling pathways (68). LPC is cleaved by the enzyme autotaxin to 
liberate LPA and choline (69). LPA is involved in various cellular processes including cell 
migration, proliferation and differentiation (69). LPA has been shown to affect fertility and 
reproduction, the formation of the nervous system as well as the development of the 
vasculature (69).  
 
 
Lysophosphatidylcholine (LPC)  
 
LPC is a product of the partial hydrolysis of PC by the enzymatic action of PLA2, which 
removes one of the FA groups. LPC have a short half-life in vivo since it is quickly 
metabolized by lysophospholipase and LPC-acyltransferase. LPC accounts for <3% of the 
phospholipids of cell membranes and 12% of phospholipids in blood plasma (70). LPC are 
involved in several different processes such as induction of phagocyte recruitment when 
released by apoptotic cells (71). Also, LPC activates endothelial cells during atherosclerosis 
(72, 73) and can change the surface properties of erythrocytes (70).  
 
LPC are known for their important functions in the development of the normal human brain 
(74). Furthermore, LPC induces pro-inflammatory cytokines such as IFN-γ secretion by a 
platelet-activating factor receptor-dependent mechanism, in peripheral blood mononuclear 
leukocytes from healthy blood donors (75).  
 
 
 
Fatty Acids (FA)  
 
FA are a carboxylic acid with a long aliphatic chain (composed of carbon and hydrogen) of 
an even number of carbon atoms. FA with an aliphatic tail of 4-6 carbons are called short-
chain FA (SCFA), medium-chain FA (MCFA) consist of 6-12 carbons, long-chain FA 
(LCFA) consist of 13-21 carbons and very long-chain FA (VLCFA) consist of 22-28 
carbons. FA belong to either saturated (no carbon-carbon double bonds, thus saturated with 
hydrogen) or unsaturated (one or more double bonds between carbon atoms) types (52). 
Mammals lack enzymes that introduce double bonds beyond carbon atoms C9 in the FA 
chain, hence, essential FA such as a-linolenic acid (ALA) and linoleic acid (LA), must be 
supplied in the diet. FA have several major functions in the body and are essential 
components of the cell membrane phospholipids and have an impact on membrane 
permeability, fluidity, anchoring of membrane-related proteins and thus cellular functions 
(76, 77).   
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There are two principal families of polyunsaturated FA (PUFA), namely omega-3 (ω-3) 
FA, and omega-6 (ω-6) FA, both are closely involved in many aspects of physiological 
regulation in the body (78). Both ω-6 and ω-3 PUFA compete for the same enzymes in the 
eicosanoid synthesis and are precursors of eicosanoids (79, 80). 
 
 
ω-3 FA 
 
ALA, as well as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) belong to 
the ω-3 family of FA. They are crucial for fetal growth, comprising the neuronal and the 
immune functions (81). They are found in green plants and fish and should be 
supplemented in the diet, such as by the consumption of fish oil. Moreover, the intake of 
specific dietary FA can modify the chemical composition of the cell membrane. For 
instance, the consumption of fish oil rich in EPA and DHA can lead to the partial 
replacement of arachidonic acid (AA) in cell membranes, altering membrane fluidity, 
which could affect binding of cytokines or alter the cytokine effect on the cells (80, 82).  
 
The metabolism of ω-3 EPA results in the formation of prostaglandin E3 (PGE3), 
thromboxane A3 (TXA3) and leukotriene B5 (LTB5), which are less biologically active than 
their ω-6 counterparts (83). Resolvin, protectins and maresins are another class of 
metabolites of ω-3 EPA and DHA, which are involved in the resolution of inflammation.  
 
 
ω-6 FA 
 
The ω-6 family of FA consists of LA and its derivatives dihomo-γ-linolenic acid (DGLA) 
and AA (78). The rich source of ω-6 FA is vegetable oils, nuts and meat. The metabolism 
of ω-6 PUFA results in the formation of pro-inflammatory mediators PGE2, TXA2 and 
LTB4. 
 
Growing literature provides the evidence of the important role of FA in skeletal muscle 
inflammation, growth, and performance (54, 84-88). Structural membrane lipids 
composition is affected by the dietary FA, which in turns alters muscle function (88). 
However, the involvement of lipids and FA in the pathogenesis of IIM has not been 
established. 
  
 
Eicosanoids  
 
Eicosanoids are a family of lipid mediators originated from 20-carbon-atom FA and 
involved in  the regulation of many physiological and pathological processes (6). The main 
classes of the potent biologically active eicosanoids are produced via the COX-pathway 
giving rise to prostaglandins and TXA2, collectively known as prostanoids, or via the 
lipoxygenase (LO)-pathway giving rise to leukotrienes and lipoxins. At low concentrations, 
prostaglandins and leukotrienes have essential physiological effects and act locally due to 
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their short half-life. Eicosanoids are produced by most types of mammalian cells and bind 
to individual receptors, exhibiting a wide range of biological functions, the effects vary 
depending on cell and receptor type.  
 
 
Biosynthesis of prostanoids  
 
Arachidonic acid (AA), a 20-carbon polyunsaturated ω-6 FA, is released from membrane 
phospholipids by cPLA2 in response to multiple stimuli. The stimuli leading to an increase 
in intracellular calcium (Ca2+) levels, induce the translocation of cPLA2 to the membrane 
and trigger hydrolysis of AA from membrane phospholipids.   
 
The released AA is further converted by COX-1 and COX-2 to prostaglandin endoperoxide 
H2 (PGH2). The COX isoforms are membrane-bound proteins and are localized to the 
endoplasmic reticulum as well as the nuclear membranes (89, 90). However, their 
expression patterns, as well as functions, differ. COX-1 is expressed constitutively in most 
cells and is the dominant source of prostanoids that serves housekeeping functions such as 
gastric cytoprotection and homeostasis (91, 92). COX-2, however, is an inducible enzyme 
upon pro-inflammatory stimuli such as cytokines (IL-1β, TNF-α and IL-6), trauma, 
hormones and growth factors and is the most important source of prostanoids during 
inflammation (92) (Figure 1). PGH2 generated by COX-1 and COX-2 then serves as a 
substrate for specific terminal synthases to produce the five primary prostanoids. The 
prostanoids family consist of PGE2, PGI2, prostaglandin D2 (PGD2), prostaglandin F2α 
(PGF2α), and TXA2. These lipid mediators are generated by various cells and have different 
important biological functions (6).   
 
In uninflamed tissue, these lipid mediators are produced at low levels, however, upon 
inflammation, the production of prostanoids is dramatically increased. Prostanoids are 
biologically active lipid compounds with hormone-like effects and have important 
functions in many physiological processes such as vascular hemostasis (93-96), 
gastrointestinal integrity (24, 97), kidney perfusion (98), and platelet aggregation (95).  
 
In the pathophysiological conditions, they contribute to the malignant and inflammatory 
processes. Prostanoids have the dual function in inflammation; they can act as pro-
inflammatory mediators and also as anti-inflammatory agents (6).  
 
They exert their biological activities in an autocrine and paracrine manner by binding to 
their cognate G-protein-coupled cell receptors (GPCR), located on the cell surface or 
nuclear membrane (Figure 1).  
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Prostanoids Receptors 
PGE2 EP1, EP2, EP3 and EP4 
PGI2 IP 
PGD2 DP1 and DP2 
PGF2α FP 
TXA2 TP 
 
 
The cellular repertoire of receptors determines the outcome of the prostanoid action, as 
certain GPCR activates specific signaling pathway (6, 99, 100). The signaling is achieved 
through the modulation of intracellular Ca2+ or cyclic adenosine monophosphate (cAMP) 
level (101).  
The prostanoids are not exclusively binding to the prostanoid receptors they are assigned by 
the nomenclature. Since all prostanoids are very similar in structure the cognate receptor 
can also bind other prostanoids with lower affinities (6, 101). One example of this takes 
place in the cardiovascular system where a high concentration of PGE2 can trigger the IP 
receptor to inhibit platelet aggregation (102) (Figure 1). 
 
 
PGES and PGE2 
 
Several PGES converts PGH2 to PGE2 (Figure 1). mPGES-1 belongs to Membrane-
Associated Proteins in Eicosanoid and Glutathione metabolism (MAPEG) family. mPGES-
1 is glutathione (GSH)-dependent terminal synthase in the PGE2 biosynthesis pathway and 
constitutes an integral membrane protein. Functionally, mPGES-1 primarily coupled with 
COX-2 and upon induction by proinflammatory stimuli such as IL-1β (103), TNF-α, and 
lipopolysaccharide (LPS) the expression of these enzymes increases and leads to an 
excessive PGE2 biosynthesis. mPGES-1 is induced by pro-inflammatory stimuli in 
fibroblasts (104), vascular endothelial cells of the inflamed tissue (103), innate immune 
cells such as neutrophils (105), macrophages and dendritic cells (106, 107).  
 
Furthermore, there are two more structurally and biologically different PGE2 synthases 
acting downstream of COX-1 and COX-2 known as microsomal prostaglandin E2 synthase 
(mPGES) -2 and cytosolic prostaglandin E2 synthase (cPGES). The latter two synthases are 
expressed constitutively and are responsible for the production of PGE2 with physiological 
functions while inducible mPGES-1 produces PGE2 usually associated with the 
pathophysiological conditions. The mPGES-1 expression is low under the normal 
physiological condition and is found in placenta, testis, prostate, mammary glands as well 
as in the bladder (3). It is also constitutively expressed in the lung, kidney, spleen, and 
stomach (108). mPGES-1 is not detectable in normal human heart or liver; however, it is 
detectable after infarctions and can be strongly induced at sites of inflammation and in 
cancer (4, 109).  
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PGE2 physiological and pathophysiological functions 
 
PGE2 have important physiological properties and is an essential player in inflammation 
and cancer.  It is a relatively stable molecule in vitro, however, in vivo, it has a very rapid 
turnover rate. PGE2 is involved in a wide array of physiological processes including 
regulation of vascular pressure, maintenance of the gastrointestinal integrity, renal function 
and female reproduction (110) (Figure 1). PGE2 mediates its effect via four GPCR (6), EP1-
EP4 and most major cell subsets of the immune system express at least one of the four EP 
receptors. PGE receptors couple to a range of intracellular signaling pathways that mediate 
the effects of receptor activation on cell functions. EP1 activates PI metabolism via Gq 
leading to the formation of inositol triphosphate with the mobilization of intercellular free 
CA2+ (6). EP2 and EP4 receptors activate adenylyl cyclase via Gs, and therefore increasing 
intercellular cAMP (6). Lastly, The EP3 receptor can couple via Gi to elevate intracellular 
calcium and inhibit cAMP generation (6).  
 
In pathological conditions, PGE2 is known as a powerful mediator of inflammation, pain 
and tissue destruction (111, 112). PGE2 is a key mediator of inflammation causing heat and 
swelling (113, 114) by stimulating vascular smooth muscle cells, causing vasodilation and 
increased blood flow into the inflamed tissue. PGE2 also mediates pain hypersensitivity by 
lowering the threshold of activation of nerve endings to pain mediators, both centrally and 
peripherally (115). PGE2 increases levels of cAMP and enhances nociceptor sensitization 
by reducing the activation threshold for sodium channels via a protein kinase A (PKA) 
pathway (116), sensitizing primary afferent neurons to inflammatory mediator bradykinin, 
as well as to other mediators (117).  
 
PGE2 have an important role in stimulating the angiogenesis, by triggering an induction of 
vascular endothelial growth factor (VEGF) production in vascular endothelial cells (118).  
PGE2 has both anti-inflammatory and pro-inflammatory functions when acting on different 
cells. PGE2 reduces the oxidative burst of activated neutrophils and inhibits TNF-α 
production in neutrophils while enhancing IL-10 production, which is an anti-inflammatory 
cytokine (105, 119). Also, PGE2 is a part of an auto-regulatory loop inducing the COX-2 
expression and consequently its own production at the site of inflammation (28).  
 
Furthermore, PGE2 modulates the adaptive immune system affecting both on B and T 
lymphocytes, by inhibiting the lineage development of B cells precursors and the 
proliferation of mature B cells while promoting IgE and IgG1 class switch (120). In T cells, 
however, PGE2 impact the T cell proliferation both in an inhibitory and stimulatory ways. 
These opposite effects could be explained by the fact that the T cell receptors, as well as 
EP2 and EP4 receptors, are competing for the recruitment of the same intercellular signaling 
molecules (121). Lastly, PGE2 has a critical role in inducing the fever response in the brain, 
inducing a hostile environment for the invading pathogens (28). 
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Prostaglandin I2 synthase (PGIS) and PGI2 
 
PGI2 is generated by the terminal synthase PGIS via the conversion of PGH2. PGIS is co-
localized with COX in the endoplasmic reticulum in endothelial cells (6). PGI2 is mainly 
produced by endothelial cells, activated monocytes and in vascular smooth muscle cells, 
and regulates the vascular tone and platelet function by acting as a potent vasodilator and 
inhibitor of platelet aggregation (96) (Figure 1).  
 
During inflammatory conditions, PGI2 and PGE2 have overlapping functions. Both 
prostaglandins cause vasodilation when binding to respective receptors on vascular smooth 
muscle cells. Another overlapping function of these two lipid mediators is the induction of 
pain hypersensitization when acting on peripheral nerve ends (96, 101).  
 
In the adaptive immune system, PGI2 has both inhibitory as well as stimulatory effects; it 
inhibits dendritic cell activation, suppresses T cell maturation and stimulatory capacities, 
and induces TH1 cell differentiation (122, 123). PGI2 has a very short half-life in vivo and in 
biological fluids. The method of choice to analyze the PGI2 synthesis is to measure levels of 
6-keto-PGF1α, a stable hydrolyzed product of PGI2 (96). 
 
 
Prostaglandin D2 synthase (PGDS) and PGD2 
 
There are two enzymes converting PGH2 to PGD2, namely lipocalin-type and hematopoietic 
PGD2 synthases (L-PGDS and H-PGDS, respectively) (Figure 1). L-PGDS is a secretory 
protein (124) expressed in the central nervous system (125), male genitals organs (126) and 
in the human heart (124), whereas H-PGDS is a cytosolic protein belonging to the 
glutathione S-transferase superfamily and is mainly expressed in immune and inflammatory 
cells (127).  
 
PGD2 is mainly produced by mast cells as well as macrophages, dendritic cells, and T cells. 
PGD2 acts through its cognate receptors, it mediates vasodilation, bronchodilation and 
inhibits platelet aggregation when bound to DP1. Through DP2 it mediates chemotaxis of 
TH2 cells, eosinophils, and basophils (101).  
 
In the brain, PGD2 is involved in regulating sleep, nociception, and temperature (101, 128). 
Moreover, PGD2 plays an essential role in allergy and inflammation (129). Both PGD2 and 
its nonenzymatic metabolite cyclopentenone 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) 
are also shown to have anti-inflammatory properties in a peroxisome proliferator-activated 
receptor γ (PPAR-γ) depended manner by inhibiting the production of COX-2 and mPGES-
1 expression (130).  
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Prostaglandin F2α synthase (PGFS) and PGF2α 
 
PGFS converts PGH2 to PGF2α which is involved in many physiologic functions including 
contraction of uterine and vascular smooth muscles (131) (Figure 1). PGF2α is also involved 
in the female reproductive cycle and is essential in the regulation of myogenesis.  
 
The FP receptor is not expressed on immune cells, and there is limited evidence of its 
involvement in inflammatory processes (6, 101). However, there is a study showing 
elevated biosynthesis of PGF2α in RA, psoriatic arthritis, reactive arthritis as wells as in 
osteoarthritis patients (132). PGF2α is a stable molecule in aqueous solution with a very 
short half-life in vivo (133). 
 
 
Thromboxane A2 synthase (TXAS) and TXA2 
 
TXA2 is synthesized by TXAS and is a very unstable molecule, rapidly hydrolyzed to its 
biologically inactive metabolite thromboxane B2 (TXB2) in vivo (134) (Figure 1). TXA2 
regulates vascular tone and platelet functions by acting as a vasoconstrictor and inducer of 
platelet aggregation (6). It is mainly produced by platelets but can be generated by other 
cell types, for instance, macrophages.  
 
TXA2 functions through two isoforms (α and β) of the TP GPCR that differ in cellular 
distribution. TP stimulation leads to platelet activation, adhesion and aggregation, as well as 
smooth muscle contraction and proliferation (95). The TP receptor is also expressed on 
dendritic cells, and when bound to TXA2 it mediates immune response by inhibiting 
dendritic cell-T cell interactions (135). In biological fluids, the method of choice to analyze 
TXA2 synthesis is to measure TXB2 levels.  
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Figure 1 | Biosynthesis of eicosanoids.  
Arachidonic acid (AA) is released from membrane phospholipids by cytosolic phospholipase A2 (cPLA2).  
Prostaglandins: cyclooxygenase (COX)-1/2 catalyzes the conversion of AA into prostaglandin H2 (PGH2). 
PGH2 is then catalyzed by different terminal synthases to several lipid mediators all with biological activity. 
Microsomal prostaglandin E2 synthase (mPGES)-1/2 and cytosolic prostaglandin E2 synthase (cPGES) 
catalyzes the conversion of PGH2 to prostaglandin E2 (PGE2). Prostacyclin (PGI2) is formed from by 
prostaglandin I2 synthase (PGIS). Lipocalin-type and hematopoietic prostaglandin D2 synthases (L-PGDS and 
H-PGDS, respectively) converts PGH2 to prostaglandin D2 (PGD2). PGH2 is also converted by prostaglandin 
F2α synthase (PGFS) and prostaglandin TXA2 synthase (TXAS) into prostaglandin F2α (PGF2α) and 
thromboxane A2 (TXA2), respectively. Leukotrienes: Arachidonate 5-lipoxygenase (5-LO) and 5-LO 
activating protein (FLAP) convert AA into arachidonic acid 5-hydroperoxide (5-HPETE) and leukotriene A4 
(LTA4). LTA4 is further metabolized by LTA4 hydrolase (LTA4 H) into leukotriene B4 (LTB4) or by LTC2 
synthase (LTC4S) into cysteinyl-leukotriene LTC4, which is further metabolized to LTD4, and LTE4. The 
effects of all eicosanoids are mediated through different G-protein coupled receptors (GPCR), associated with 
different signal transduction pathways; acting on either the cyclic adenosine monophosphate (cAMP) or/and 
the calcium (CA2+) release.  
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cPLA2
Vasodilation Vasodilation                 Vasodilation Vasocontraction           Chemotaxis
Nociception Nociception Nociception
Angiogenesis Chemotaxis
Fever 
Inflammatory-related functions
Vascular pressure      Platelet inhibition Bronchodilation         Parturition           Platelet activation
GI integrity (anti-thrombotic) Sleep regulation         Myogenesis         (pro-thrombotic)
Renal function
Female reproduction
Physiological functions
Proliferation Anti-migration Proliferation Proliferation Proliferation 
Fusion Fusion Anti-fusion Fusion Differentiation
Differentiation Anti-differentiation      Anti-apoptosis
Myoblasts-related functions
PGE2 PGI2 PGD2 PGF2α TXA2 LTB4
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Biosynthesis and function of leukotrienes  
 
Leukotrienes are powerful and potent inflammatory mediators and have pathophysiological 
functions in allergic reactions as well as in respiratory and inflammatory diseases e.g. 
asthma and arthritis (136) (Figure 1). The biosynthesis of leukotrienes from AA, 
predominately by cells of myeloid origin, is carried out by arachidonate 5-lipoxygenase (5-
LO) (Figure 1).   
This cellular process is dependent on the assistance of the helper protein, 5-LO activating 
protein (FLAP). FLAP is crucial for efficient utilization of the substrate AA (137-139). AA 
is converted by 5-LO interacting with FLAP to arachidonic acid 5-hydroperoxide (5-
HPETE) that is an intermediate in the production of leukotriene A4 (LTA4). Leukotriene A4 
hydrolase (LTA4H) converts in turn LTA4 to leukotriene B4 (LTB4).  
LTB4 is synthesized predominately by neutrophils and is a powerful chemotactic mediator, 
binding to its cognate receptors leukotrienes B4 receptor 1 and 2 (BLTR1 and BLTR2) (140) 
(Figure 1). There are several therapeutic targets on the market targeting the leukotriene 
pathway by working either as receptor antagonist or inhibiting the synthesis of leukotrienes 
(141).  
 
Moreover, the regulation of vascular and smooth muscle responses takes place via the 
action of cysteinyl leukotrienes (CysLT), including leukotrienes C4 (LTC4), leukotrienes D4 
(LTD4) and leukotrienes E4 (LTE4).  LTA4 is conjugated with glutathione and forms LTC4 
via the action of leukotriene C4 synthase (LTC4S). LTC4 can be converted to form LTD4 and 
LTE4, which retain biological activity  (137, 138). LTC4S deficient mice have been shown 
to be resistant to asthmatic challenges (142) (Figure 1).  
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mPGES-1 
This section will focus on mPGES-1 structure and function in rheumatic diseases as well as 
in cardiovascular safety.  
 
 
 
mPGES-1 structure, regulation and function  
 
The human mPGES-1 gene is situated on chromosome 9p34.3 and contains three exons and 
two introns (143, 144). The mPGES-1 protein is a homotrimer, and each monomer contains 
four transmembranes (TM) α –helixes, in which the hydrophobic helix transverses the 
membrane. The charge distribution of mPGES-1 suggests that the N-terminus and C-
terminus face the lumen of the endoplasmic reticulum (28). The cleft between TM helix I of 
one monomer and TM IV of a neighboring monomer constitutes the PGH2 entry point to 
the active site where glutathione resides. The mPGES-1 harbors three distinct active site 
cavities inside the membrane-spanning region in each monomer interface of the trimeric 
structure. In a molecular dynamics simulation, it was indicated that only one substrate 
molecule could bind to one of the pockets and form the active complex. This suggests that 
mPGES-1 trimer has only one pocket active at any given time i.e. third of the sites 
reactivity (145).  
 
There is an extra domain reported in the crystal structure of mPGES-1 which is not found in 
other members of the MAPEG super family of proteins represented by a small cytosolic 
domain inserted between transmembrane helix I and II (146). Furthermore, it has been 
shown that the mPGES-1 has a cone-shaped cavity extending from the cytosolic side of the 
membrane-spanning region, which is suggested to be a substrate PGH2 access cavity (146). 
Moreover, the cofactor GSH adopts a horse-shoe shaped conformation in the active site of 
mPGES-1 and enters via the cytosol (146).  
 
Several catalytic mechanisms have been proposed for mPGES-1 (146-148) based on 
predictions and structural studies, and initially Serine (Ser) 127 was thought to be important 
for the catalytically activity of mPGES-1. In contrast, a recent study investigating the 
significance of several amino acid residues, all close to the GSH molecule, demonstrated 
that arginine (Arg) 126 and aspartate (Asp) 49 are important for catalytic activity of 
mPGES-1, whereas Ser127 is not (147, 149).  
 
The expression of mPGES-1 is primarily regulated at the transcriptional level (150) and 
also post-transcriptional mechanisms are involved, e.g. via mRNA stability (151). 
However, whether mPGES-1 might be regulated by alternative splicing has not been 
elucidated. There are several signal transduction pathways impacting mPGES-1 expression. 
Thus, transcriptional factor early growth response protein 1 (Egr-1) binds to the proximal 
GC-box in the promotor region and induces transcription of the mouse and human mPGES-
1 gene (150). c-Jun N-terminal kinase (JNK) and NF-KB are two signal transduction 
pathways for mPGES-1 regulation by TNF-α in gingival fibroblasts (152). Inhibition of 
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these two TNF-α-activated signal pathways reduces the expression level of mPGES-1 
(152). Furthermore, extracellular signal–regulated kinases 1 and 2 (ERK 1/2) and 
P38 mitogen-activated protein kinases (MPKA) are two signal transduction pathways 
involved in mPGES-1 regulation by IL-1β in osteoarthritic human cartilage (153). 
Moreover, PGE2 might increase the expression of mPGES-1 via positive feedback in certain 
cells. Hence activation of the PGE2/EP2/PKA signaling pathway induces the 
phosphorylation of the cAMP-response elements binding protein, resulting in 
transcriptional activation of mPGES-1 in macrophages stimulated with LPS (154). It has 
also been shown JNK can participate in the regulation of mPGES-1 protein synthesis in 
cardiomyocytes (155).   
 
 
 
mPGES-1 in rheumatic diseases   
 
The AA cascade and the production of eicosanoids are activated in rheumatic patients; 
during inflammation, an induction of the Ca2+-signaling pathways and cytokine-dependent 
induction of related enzymes occurs. The expression of COX-2 and mPGES-1, as well as 
the expression of 5-LO and 15-LO, are upregulated during inflammation, resulting in the 
activation of eicosanoid production (20, 21). 
 
 
mPGES-1 in the pathogenesis of RA 
 
In vitro studies of synovial fluid mononuclear cells from RA joint have shown upregulated 
expression of mPGES-1 and COX-2 upon pro-inflammatory stimuli such as IL-1β, TNF-α 
or LPS, leading to elevated PGE2 production (156, 157). Consequently, synovial fluid from 
untreated RA patients demonstrates prominent levels of prostaglandins such as PGE2, 
PGF2α, TXB2, PGD2 and 6-keto-PGF1α (non-enzymatically hydrolyzed PGI2) (158).  
 
mPGES-1 and PGE2 are markedly upregulated due to the inflammatory milieu in the joint, 
contributing to heat, pain as well as recruitment and activation of inflammatory cells (6). 
RA patients have high expression of mPGES-1 and therefore elevated levels of PGE2 in the 
inflamed synovial tissue (159). mPGES-1 gene polymorphism has been shown to be 
associated with earlier disease onset as well as higher baseline disease activity score (160). 
T lymphocytes do not express mPGES-1 (159), however, there is a study demonstrating 
mPGES-1 expression in B lymphocytes (161). 
 
mPGES-1 is known to be functionally coupled to COX-2 (112, 162) and has been 
demonstrated to be co-localized in the RA synovial fluid mononuclear cells as well as in 
cells of the RA synovial lining layer(157). Their expression is also upregulated in synovial 
fibroblasts and macrophages of the sub-lining layer, as well as in vascular endothelial cells 
(161). At the sub-cellular level, the co-localization of these enzymes has been reported in 
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the endoplasmic reticulum as well as in the perinuclear membrane (112).  Thus, these 
enzymes show an efficient coupling function. 
 
The induced expression of mPGES-1 and COX-2 in the synovium of RA patients remained 
unaffected by TNF blockade (161, 163) and B cell depletion therapy (161), indicating a 
need for complementary therapy with mPGES-1 inhibitors for optimal anti-inflammatory 
treatment. However, the expression of mPGES-1 in primary human chondrocytes have been 
shown to be inhibited in a dose-dependent manner with a certain DMARD aurothiomalate 
(164). 
 
 
mPGES-1 in the pathogenesis of IIM 
 
The expression and localization of mPGES-1, as well as other enzymes related to the PGE2 
biosynthesis, have been shown to be enhanced in muscle tissue from PM and DM patients 
compared to healthy individuals, implicating a role of the PGE2 pathway in the pathogenesis 
of inflammatory myositis.  
 
Analysis by double immunofluorescence confirmed a most prevalent expression of 
mPGES-1 in macrophages in muscle tissue from myositis patients (20). Furthermore, 
immunosuppressive treatment with GC in combination with DMARDs affected the 
expression of COX-2 while mPGES-1 expression in inflamed muscle was not changed (20). 
An explanation could be that in order to suppress mPGES-1 expression, a higher dosage of 
GC is needed (157).   
 
Importantly,  mPGES-1 is induced in rheumatic diseases by a wide range of different 
stimuli such as hypoxia (165), mechanical stress (166), adipokines (167, 168), smoking 
(169) and cytokines (170, 171), causing persistent expression in RA synovium and 
inflamed muscle in PM and DM patients. Therefore, the inhibition of the PGE2 
biosynthesis, by targeting mPGES-1, might complement different anti-rheumatic therapies 
to gain an ideal anti-inflammatory control of the disease. 
 
 
mPGES-1 as a therapeutic target in rheumatic diseases  
 
mPGES-1 has been proven to be strongly upregulated at sites of inflammation in RA and in 
myositis (20, 157, 159) and is not properly targeted by current anti-rheumatic treatments 
(20, 157, 161, 172). Therefore, mPGES-1 might contribute to the subclinical inflammation 
and later relapses of the diseases.  
 
The role of mPGES-1 as an alternative therapeutic target for anti-inflammatory treatment of 
rheumatic diseases has been emphasized by studies in experimental models. Multiple 
studies evidence that genetic deletion or pharmacological inhibition of mPGES-1 is 
protective in several experimental models of inflammatory disorders (4, 20). The severity 
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and incidence of collagen-induced arthritis (CIA) are reduced in mPGES-1 deficient mice. 
These mice exhibit less pain, joint destruction and reduced levels of anti-collagen type II 
antibodies compared with wild-type (WT) mice (114).  
Similarly, in a collagen-antibody-induced (CAIA) model of human RA, mPGES-1 deficient 
mice exhibited less severity of the disease (173). In addition, reduced synovial hyperplasia, 
less infiltration of inflammatory cells as well a reduction of osteoclast number has been 
reported (114, 173, 174). Moreover, the inhibition or deletion of mPGES-1 does not alter 
blood pressure or predispose to thrombosis in mouse models (175). 
 
These data together illustrate that the deletion of mPGES-1 reduces inflammatory response, 
could potentially be cardioprotective and is unlikely to cause side effects seen with 
selective COX-2 inhibitors.  
 
While COX-1 is considered to be a housekeeping gene and is expressed constitutively in 
most cells including platelets and endothelial cells (6, 176), the COX-2 expression is highly 
restricted to the vasculature (177) and the kidney (178), and is up-regulated by pro-
inflammatory stimuli. Studies in a mouse model of thrombosis have demonstrated that 
deletion of COX-2 in the vasculature reduces PGI-M in urine and predisposes the animal to 
both hypertension and thrombosis (179). Furthermore, selective deletion of COX-2 in 
mouse cardiomyocytes causes decreased cardiac output, and enhanced susceptibility to 
induce arrhythmogenesis (180). Because of the side effects related to COX-2 inhibitors, the 
developments of new drugs targeting prostaglandins in inflammation as well as in cancer 
(181, 182) has been prevented. Inhibitors of mPGES-1 have been proposed as an alternative 
treatment that comprises the therapeutic potential of NSAIDs but lacks severe side effects 
associated with NSAIDs. 
 
The essential characteristics of mPGES-1 inhibitors should be improved efficacy and 
cardiovascular safety as compared to COX inhibitors. However, knowledge on the effects 
of mPGES-1 inhibition on the cardiovascular system, especially on platelet and endothelial 
functions is limited.  Platelets express PGE2 receptors, and their functions might be affected 
by PGE2. Studies of the role of mPGES-1 in platelet activation and aggregation will clarify 
the cardiovascular safety of mPGES-1 inhibitors. Moreover, comparative studies of the 
effects of the mPGES-1 and COX-2 inhibitors on cellular and molecular processes will 
identify novel biomarkers and pathways related to anti-inflammatory or side effects of the 
drugs and eventually lead to improved anti-inflammatory treatment.  
 
 
 
mPGES-1 and cardiovascular safety  
 
Prostaglandins are important in the cardiovascular system where they have both 
homeostasis and pathological functions. PGE2 is involved in the regulation of blood 
pressure whereas the TXA2 and PGI2 balance is essential for platelet activation. PGE2 is 
present in atherosclerotic plaque (183). It has been shown that macrophages produce high 
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nanomolar concentrations of PGE2, which are implicated in cardiovascular pathologies such 
as plaque rupture and abdominal aortic aneurysm formation (184). There is evidence 
supporting that PGE2 derived from atherosclerotic plaque can exit the plaque and act 
directly on platelets (185).  
 
In endothelial cells COX-1 and COX-2 produce PGI2, which is a cardioprotective hormone, 
whilst platelet produce TXA2 which could contribute to thrombosis (6, 94). An dysbalance 
between these two metabolites, as the results from treatments with Coxibs, can lead to 
severe cardiovascular side effects.  Therefore, mPGES-1 inhibition is thought to be a novel 
mechanism of a NSAID with no or diminished cardiovascular side effects.  
 
There are several studies implicating that mPGES-1 inhibitors might be more 
cardioprotective compared to COX-2 inhibitors (186, 187). In a mouse model of thrombotic 
carotid artery occlusion, genetic deletion of mPGES-1 did not accelerate thrombogenesis 
(175). Furthermore, suppression of PGE2 accounts for the protective effect of mPGES-1 
deletion in a model of atherosclerosis, leading to a redirection of PGH2 to PGI2 production 
which is thought to be the dominant contributor to a favorable thrombogenic profile (187). 
Additional studies have demonstrated that global deletion of mPGES-1 has a favorable 
atheroprotective impact and delays aneurysm formation in hyperlipidemic mice (188, 189).  
 
 
mPGES-1/PGE2 pathway in platelet functions 
 
One of the major functions of platelets is to stop bleeding at the site of interrupted 
endothelium 190, and they are only found in mammals. Platelets lack a cell nucleus and are 
fragments of the megakaryocytes of the bone marrow. Beyond their role in hemostasis, 
platelets have been shown to promote inflammation by releasing cytokines, chemokines 
and other lipid mediators (190, 191) and contribute to the pathophysiology of RA and the 
cardiovascular system  (191, 192). The activation platelets markers P-selectin, CD40L as 
wells as platelet-derived microparticles (PMP) are frequently found accumulated in blood 
and synovial fluid of RA patients (193-195).   
 
The release of microparticles (MP) by platelets modulate some inflammatory processes 
(196). MP are small membrane-coated vesicles produced by budding and fission of the 
plasma membrane of activated or apoptotic cells (197). MP display surface proteins from 
their parental cells and are considered to be biological messengers by exhibiting surface 
phospholipids, cellular origin antigens, and cytokines. In some cases, they could contain 
mRNA and microRNA (198).  
 
MP have also shown to be involved in the pathogenesis of RA (193, 194). Activated 
platelets can generate PMP which may play a role in the pathogenesis of RA and the 
maintenance of the chronic inflammation. PMP have been identified in joint fluid from RA 
as well as in joint fluid from patients with other inflammatory diseases.  
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During platelet activation, PMP are produced by the shedding of the platelet membrane 
(194). PMP containing IL-1β have been shown to have pro-inflammatory properties by 
initiating cytokine response of synovial fibroblasts (193, 194). Furthermore, enhanced 
platelet activation and accumulation of PMP in the synovial fluid of inflamed joints from 
RA patients have been demonstrated (199).  
 
Soluble P-selectin is an indicator of platelet activation and has been shown elevated in 
plasma from patients with RA compared to healthy individuals. A correlation between 
disease activity and the levels of detectable platelet-derived proteins such as soluble P-
selectin and CD40 ligand (CD40L) in plasma (195) has also been reported.  Interestingly, 
MPs derived from leukocytes strongly induce COX-2 and mPGES-1 expression in RA 
synovial fibroblasts and shown to stimulate the production of PGE2 (200).  
 
Furthermore, platelet-depleted mice display a decrease in inflammatory arthritis as 
evaluated by clinical scoring and by histological analysis. Therefore, platelets are involved 
in the pathogenesis of inflammatory arthritis in mice (194).  
 
Human and murine platelets do not express mPGES-1 and as a consequence cannot produce 
inducible PGE2 (186, 201). However, platelets do express PGE2 receptors, so their functions 
might be modulated by the mPGES-1/PGE2 pathway, induced in inflammatory conditions. 
The most abundant receptors for PGE2 are EP3 and EP4, both of them expressed on human 
platelets (202). In addition, EP2 is also expressed on human platelets, while EP1 has not 
been detected on platelets thus far (202-204).  
 
Together, these data suggest that platelets and PMP contribute to the pathogenesis of RA 
and the maintenance of the chronic inflammation and platelets have been suggested as a 
candidate to link systemic inflammation, cardiovascular risk and active synovitis in RA 
patients. Studies of the role of mPGES-1 in platelet activation and aggregation intend to 
further elucidate the anti-inflammatory actions and cardiovascular safety of mPGES-1 
inhibitors.  
 
 
mPGES-1 and the endothelial function 
 
Endothelial cells play a vital role in a wide range of biological processes including 
haemostasis, wound healing, angiogenesis and inflammatory disorders (205). They produce 
AA metabolites, hence, regulating coagulation, vascular tone and immune response. It has 
been shown that macro vessel-derived endothelial cells from fetal and adults do not produce 
PGE2 enzymatically (206). The same authors also demonstrated that macro vessel-derived 
endothelial cells do not express mPGES-1 (207, 208). However, other studies have 
demonstrated the expression of mPGES-1 in human microvascular endothelial cells (209).  
 
Tumor cells induce the expression of COX-2 and mPGES-1 expression in microvascular 
endothelial cells mainly via IL-1 receptor activation (208). In a study with COX-2 knock-
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out (KO) mice, the authors showed that COX-2 profoundly limits atherosclerosis and the 
protection is independent of local PGI2 release (210). Therefore, more studies on new 
targets and pathways to define the COX/mPGES-1/NSAID/cardiovascular risk axis are 
required. In line, a link between the inhibition of COX-2 and the endothelial nitric oxide 
synthase (eNOS) pathway has recently been revealed (211). This finding sheds new light on 
the mechanisms how COX-2 and PGI2 protect the cardiovascular system. In fact, the 
naturally occurring eNOS inhibitor, asymmetric dimethylarginine (ADMA) (212) is 
elevated in patients taking Coxibs, which may lead to vascular dysfunction (211, 213).  
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Lipid mediators in IIM 
This section will focus on prostaglandins and FA function in skeletal muscle. 
 
 
 
Prostaglandins and their function in skeletal muscle  
 
Skeletal muscle tissue is composed of several different cells types including myocytes, 
fibroblasts, endothelial cells and smooth muscle cells; all these cells could be a source of 
prostaglandins. Inflammatory cells such as neutrophils, macrophages, and mast cells are 
also recruited to the muscle tissue during inflammation or injury and able to producing 
prostaglandins. Prostaglandins have been appointed essential functions in muscle growth by 
controlling different steps of myogenesis (214-217). These include survival (218), 
proliferation (215, 216), differentiation (215), as well as migration and fusion of myoblast 
(214) (Figure 1).  
 
PGE2 is also produced by human and mouse myoblasts during proliferation and 
differentiation (216). PGE2 regulates muscle growth by promoting proliferation, 
differentiation and fusion of myoblasts (215, 216).  
 
PGI2 affects myogenesis via negative regulation of the myoblast migration. It also promotes 
cell-cell contact and induces cell fusion without affecting myoblast differentiation (214). 
PGI2 has been identified in primary mouse myoblasts at different stages of myogenesis. 
PGIS and the PGI2 receptor are expressed by mouse primary myoblasts (214).  
 
PGD2 enhances cell proliferation, reduces myoblast fusion and inhibits myotube formation 
(219). Both PGD2 and its metabolite 15d-PGJ2 are associated with inhibition of myogenesis 
(219). 
 
PGF2α is produced by human and mouse myoblasts during proliferation and differentiation 
in to muscle cells (216). PGF2α has been shown to be essential for the induction of myoblast 
proliferation and promotes the fusion of myoblast to myotubes (215, 216),  as well as 
increases myotube size by preventing myoblast apoptosis (218). FP receptors have been 
shown to be expressed in differentiated muscle cells (218).  
 
In muscle from healthy individuals, the levels of prostaglandins can become elevated by 
several different factors such as physical exercise, that induce the release of PGE2, PGF2α, 
and 6-keto- PGF1α which promote vasodilation in this organ. Another factor that contributes 
to the release of prostaglandins by muscle cells is hypoxia that leads to activation of cPLA2 
and subsequently increased levels of AA (220). 
 
Since prostaglandins are implicated in muscle cell differentiation and muscle growth, they 
are also likely to be important in muscle repair. Anti-inflammatory treatment with NSAIDs 
or GC may in this context has negative effects in restoring muscle tissue after damage. 
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Prostaglandin production in muscle tissue might be enhanced in response to inflammatory 
stimuli and further promotes pain, inflammation and muscle wasting.  
 
 
 
COX and 5-LO pathways in IIM 
 
The expressions of mPGES-1, COX-1 and COX-2 are increased in muscle tissue from 
myositis patients in comparison to healthy individuals (159). Conventional 
immunosuppressive treatment of myositis patients including GC and immunosuppressive 
drugs downregulates the expression of COX-2 in muscle tissue from patients. Interestingly, 
the expression of mPGES-1 and COX-1 were not changed after treatment. This data 
suggests a potential role of these enzymes in persistent inflammation in myositis (20).  
 
It has also been demonstrated that the LTB4 pathway is upregulated in muscle tissue from 
patients with myositis. There is a negative correlation between the LTB4 production and the 
muscle performance in these patients, suggesting a possible role for LTB4 in muscle 
weakness (21). 
 
 
 
FA and their functions in skeletal muscle  
 
It is well established that lipid mediators such as prostaglandins and leukotrienes are 
involved in myogenesis, muscular pain, and inflammation, and thus may contribute to the 
pathogenesis of myositis. However, modifications in membrane FA composition of 
inflammatory cells can change the production of inflammatory mediators such as 
eicosanoids, cytokines, and adhesion molecules, and accordingly, modulate the 
inflammatory processes in the skeletal muscle.  
 
Patients with a chronic autoimmune disease such as RA, systemic lupus erythematosus 
(SLE) and juvenile arthritis have altered FA composition in plasma or blood cells compared 
to healthy individuals (53, 221-223). There are several reasons for these alterations of FA 
profiles, such as changes in the dietary intake, dysregulation of FA metabolism (55), 
lifestyle changes leading to less exercising (224, 225), inflammatory processes and the GC 
treatment (223). It has been shown that conventional immunosuppressive treatment has 
substantial consequences on the expression of genes related to lipid and FA metabolism in 
skeletal muscle tissue from myositis patients (226). This suggests that changes in the lipid 
and FA profiles could contribute to the persistent muscle weakness often seen in patients 
with myositis despite treatment.  
 
It is well recognized that FA have a great impact on skeletal muscle growth, functions and 
inflammation (54, 78, 84, 85, 227). Treatment with different FA affects the proliferation 
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and differentiation of skeletal muscle cells in vitro (85-87), while dietary supplementation 
with certain PUFA affect skeletal muscle performance in experimental animal models and 
humans (88, 228-230). Saturated FA (SFA) dramatically increased the expression of COX-
2 and consequently the production of PGE2 in mouse skeletal muscle cells. In contrast, 
PUFA did not have this effect, instead, they abolished the overexpression of COX-2 caused 
by SFA (84). Lee and cowers have shown that SFA but not PUFA induced the expression 
of COX-2 mediated through the activation of Toll-like receptor 4 and 2 (231, 232).  
 
Interestingly, an association of specific and distinct FA profiles with different disease 
markers and muscle strength has been determined in a mouse model of Duchenne muscular 
dystrophy. These results suggest that profiling the FA composition of tissue lipids could be 
a beneficial strategy for finding predictive biomarkers as well as potential therapeutic 
targets in muscle diseases (86). Lipid dysregulation might lead to the generation of 
lipotoxic mediators which could contribute to cell dysfunction or death. However, whether 
dysregulation of lipid and FA metabolism is involved in the pathogenesis of myositis and 
impaired muscle performance has not been elucidated. 
 
 
 
Dietary fats and exercise alters FA composition  
 
FA influence skeletal muscle growth and functions as well as participate in regulating 
inflammation. There are several factors affecting the composition of FA in skeletal muscle, 
which is at least partly influenced by the diet. Serum FA concentration reflects to some 
degree the composition of dietary fat (55). Although, the correlation between the estimated 
intake of specific FA and the proportions in the tissue varies for different FA (55, 78), there 
is a significant relationship between the dietary intake of PUFA and the equivalent 
proportions of the same FA in the plasma (78, 80).  
 
Dietary FA have direct influence on skeletal muscle contractile performance and could 
possibly contribute to the muscle fatigue (229). Substantial changes in the FA composition 
arise throughout myogenic differentiation, whereas supplementation with diverse FA alters 
the proliferation and differentiation of skeletal muscle cells (85, 87, 233). Indeed, it has 
been demonstrated, that by enriching certain type of PUFA in the diet, a positive effect on 
running endurance, contractile recovery after exercise and skeletal muscle fatigue can be 
achieved in animal models (88, 228, 229). Furthermore, PUFA supplementation was 
associated with the improved rate of muscle protein synthesis (234) in humans as well as 
higher muscle mass and strength in (230, 235). 
 
A randomized, double-blind controlled study has demonstrated anti-inflammatory effects of 
fish oil in early RA patients. Moreover, there are results suggesting that marine-derived ω-3 
PUFA have beneficial effects on reducing the levels of LTB4 in RA patients (236).  
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Moreover, studies clearly shows that physical exercise could change the FA composition in 
skeletal muscle (224) and could consequently affect the muscle function by affecting the 
FA composition and membrane fluidity.  
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AIMS 
The overall aim of this thesis is to gain a new and better understanding of the involvement 
of lipid mediators in rheumatic diseases to improve treatment of patients. The author of this 
thesis has performed studies on catalytic activity and cardiovascular safety of mPGES-1 in 
the hope of adding more support for the development of mPGES-1 inhibitors. The author 
has also investigated dysregulated lipid metabolism in IIM patients to provide more 
knowledge on disease pathogenesis and to explore potential biomarkers of disease activity 
and treatment. 
  
 
Specific aims   
 
• To further determine the catalytic mechanism of mPGES-1 activity by site-directed 
mutagenesis. 
 
• To examine effects of mPGES-1 deletion on platelet functions during inflammation.  
 
• To investigate how mPGES-1, PGIS, and COX-2 influence vascular and renal 
pathways associated with ADMA and eNOS. 
 
• To examine effects of the conventional immunosuppressive treatment on global 
gene expression profiles in skeletal muscle from myositis patients. 
 
• To analyze lipid/FA-profiles in serum from patients with PM/DM in comparison to 
healthy individuals (HI) and response to conventional immunosuppressive 
treatment.
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EXPERIMENTAL PROCEDURES 
In this following section, a brief description of the methods used in Paper I to Paper V will 
be presented and discussed. Only methods directly employed by the author of this thesis 
were selected to be reviewed. This section will primarily provide some general aspects of 
the methods including advantages and disadvantages. Detailed methods descriptions can be 
found in the respective paper and the references therein.  
 
 
Membrane protein over-expression 
 
mPGES-1 is a membrane protein that naturally occurs at low levels in membrane from 
different cells and tissues. In rat liver, up to 5% of the total protein isolated from membrane 
fractions after stimuli with pro-inflammatory cytokines could be accounted for the mPGES-
1 protein (237, 238).  
 
To overexpress protein of interest, bacterial over-expression was applied. The recombinant 
DNA technology was first described by Cohen and Boyer, where they introduced foreign 
DNA into the host cell Escherichia coli (E. coli)  (239, 240), allowing for rapid genetic 
manipulation (241) in a short time.  
 
In short, the first step was to identify and isolate the gene of interest. Restriction enzymes 
were used to cut DNA at or near the specific recognition nucleotide sequences known as 
restriction sites, giving specific short fragments. The DNA was then inserted into the 
plasmid by DNA ligase, an enzyme that facilitates the join of DNA strands together by 
catalyzing the formation of phosphodiester bonds. The manipulated plasmid is called a 
vector and carries the gene of interest.  
 
 
 
 
 
 
 
 
 
Figure 2 | The illustration of bacterial expression procedure. 
Restriction enzymes were used to cut DNA and plasmid of interest. DNA was inserted by DNA ligation to the 
plasmid. The plasmid was then transformed into the desired host followed by a positive clone selection and 
big-scale protein expansion.  
 
 
 
Insertion of 
DNA to plasmid
Protein expansionRestriction enzymes cuts 
open the plasmid 
Restriction enzymes cuts DNA 
sequence of interest 
Selection of positive 
clones
Plasmid 
transformedtion into 
E.coli
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The construction of recombinant DNA was followed by transforming the recombinant 
DNA into the host cell, E. coli, a gram-negative rod-shaped bacterium (242). Screening by 
selecting positive clones was done after transformation of the host cells (243). Followed by 
a big-scale protein expansion in terrific broth (TB) media induced by isopropyl β-D-1-
thiogalactopyranoside (IPTG), an inducer that triggers transcription of the lac operon to 
induce protein expression, the mPGES-1 gene is under the control of lac operon (Figure 2).  
 
The main advantage of this method includes large quantities of desired recombinant protein 
expressed in a relatively short period of time due to the rapid proliferation of E. coli. One 
disadvantage of this system is the lack of many enzymes that eukaryotic organisms use for 
post-translational modifications of proteins. Also, this system can only produce a few 
functional proteins. Another thing to bear in mind is the risk of contaminations with 
endotoxins, particular if the protein will be used in, in vivo or in vitro.  
 
This method was applied in Paper I where the catalytic function of mPGES-1 was studied. 
The protocol used for the expression, subcellular fractionation, and purification to 
homogeneity has previously been established and described (244).  
 
 
PGE2 activity assay  
 
To measure the mPGES-1 enzyme activity in vitro, the established method was used (162). 
Briefly, mPGES-1 catalyzes the isomerization of PGH2 to PGE2 (3). The substrate PGH2 is 
unstable in aqueous solution, and at room temperature, for these reasons, it is necessary to 
aliquot the acetone dissolved substrate on dry ice prior to the experiment. These steps are 
crucial in avoiding background noise as well as non-enzymatic degradation of PGH2 into 
PGE2 and PGD2.  
Each sample was diluted in the activity assay buffer containing potassium buffer to a final 
volume of 100μl. Each sample was then incubated with PGH2 for 60 seconds at room 
temperature, in duplicates. As controls, denatured by boiling samples were included.  The 
reaction was then terminated by the addition of the FeCl2 solution (245) and the samples 
were put on wet ice before the lipid isolation by solid-phase extraction (SPE), to isolate 
lipids.  
Into each sample, the internal standard was added to estimate the extraction efficiency. A 
standard curve was also included in the experiment in order to quantify the products in the 
sample. Samples were then separated by high-performance liquid chromatography coupled 
to a mass spectrometer (HPLC-MS). The chromatograms were integrated, and the area 
under the curve of each peak was then quantified.  
 
This assay is an excellent versatile assay to use when analyzing the enzymatic activity of 
mPGES-1. The condition such as incubation time, temperature as well as the concentration 
of protein can easily be modified. The assay is sensitive and can detect levels in the low 
picomole range. One disadvantage is that the method is time-consuming since there is a 
limitation to how many samples that could be analyzed during a single day.  
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This method was used in Paper I to measure the activity of native mPGES-1 as well as 
mPGES-1 variants expressed in E. coli.  
 
 
Western blot   
 
To identify specific proteins, western blot also known as immunoblot analysis was applied. 
western blot is used as an analytic technique to identify and semi-quantify specific proteins 
in complex protein mixtures. The principles behind the technique are protein separation by 
electrophoresis (246).  
 
In short, samples, either isolated cells or tissue were homogenized mechanically by a 
homogenizer or by sonication after the addition of lysis buffer. To avoid protein denaturing 
and degradation, samples were prepared on wet ice, and anti-proteases were added to the 
lysis buffer. Proteins were then separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE).  
Strong reducing agents was used to prevent secondary and tertiary structure and thus 
allowing separation of proteins by their masses. Sampled proteins get negatively charged by 
the SDS and move to the positively charged electrode through the acrylamide gel. Smaller 
proteins migrate faster in the gel whereas the larger proteins get trapped, thus leading to a 
protein separation according to size.  
A visual protein ladder was used to estimate the size of the target protein. Proteins within 
the gel were transferred to a non-specific binding membrane, to make the proteins 
accessible for antibody detection. This binding is due to hydrophobic interactions as well as 
charged interactions between the membrane and proteins.  
 
 
 
Figure 3 | Schematic overview of western blot procedure. 
Samples either cells or tissue were lysed in lysis buffer supplemented with anti-proteases, followed by 
reduction and denaturation of the samples before gel electrophoresis. Proteins were transferred to a membrane 
and incubated with the primary antibody overnight. Before and after the secondary antibody incubation, the 
membrane was washed and subsequently developed.  
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Blocking of non-specific binding by diluted protein solution was done to avoid the antibody 
binding to the membrane which has protein binding properties. This step is crucial to avoid 
the antibody binding to the membrane other than on the binding site of the specific target 
protein, thus to avoid false positive binding and reduce the background. The membrane was 
incubated with the primary antibody with gentle agitation overnight at 4ºC, followed by 
rinsing of the membrane to remove unbound primary antibody.  
The secondary antibody linked to horseradish peroxidase (HRP) which is a reporter 
enzyme, was added to record the signal. The chemiluminescent agent was cleaved to get the 
production of luminescence which is in proportion to the amount of the protein. A sensitive 
photographic film was placed on the membrane, and the image of the antibodies bound to 
the blot was visualized (247) (Figure 3).  
 
The biggest advantage of using Western blot analysis is the high sensitivity of the method, 
allowing detecting as little as 0.1 nanogram protein in the sample. Although great 
advantages, Western blot is a delicate process which requires precision in every step for 
proper identification of proteins.  
 
This method was applied in Paper I, Paper II and Paper IV.  
In Paper I the method was used to investigate the protein expression of WT mPGES-1 and 
variants. In Paper II the method was applied to identify whether platelets express mPGES-
1 or not. In Paper IV the method was used to validate the gene expression profiling data.  
 
 
In vivo model of inflammation  
 
To investigate whether mPGES-1 deletion might have beneficial effects on platelet-
mediated function as well as if it influences pathways associated with ADMA and eNOS 
during inflammation, a mouse in vivo model was applied. Mice with a deletion of the Ptges 
gene, which encodes mPGES-1 and on a DBA/1lacJ genetic background, were generated 
by breeding heterozygous littermates as previously described (114).  
 
In studies of pathways associated with ADMA and eNOS, mPGES-1+/+ and mPGES-1-/- 
treated with 100mg/kg parecoxib in drinking water for 5 days. After sacrifice of mice with 
carbon dioxide, blood from the inferior vena cava, and urine was collected, as well as the 
aortic ring and kidney tissue were collected from mice. 
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In studies of platelet-mediated function, WT (+/+) and mPGES-1 KO (-/-) mice were injected 
with 2μg of LPS or saline, intraperitoneally (i.p.) for 24 hours. After anesthetization of 
mice with isoflurane, blood was collected by cardiac puncture, furthermore, mouse liver 
and spleen tissue were collected (Figure 4).  
 
 
Figure 4 | Schematic 
overview of the in vivo 
mouse model. 
mPGES-1+/+ and 
mPGES-1-/- were 
injected with 2μg LPS. 
After 24 hours’ blood, 
spleen and liver were 
collected.  
 
 
Animal experiment in vivo remains a crucial step for the validation of in vitro experimental 
findings. It is an important tool to use when validating a drug target and ensuring the safety 
of the drug to improve the human health. One disadvantage with this method is that 
although the animals used have similar anatomy as the humans, the reaction of the drug 
tested in animals could be quite different from the reaction in humans.  
 
This method was used in Paper II and Paper III. 
In Paper II the method was used in order to investigate effects of mPGES-1 deletion on 
platelet-mediated function during inflammation. In Paper III the method was used to 
investigate beneficial effects of mPGES-1 deletion compared to COX-2 inhibitors.  
 
 
Flow cytometry  
 
Flow cytometry is a laser-based technology employed predominately in cell sorting, cell 
counting, as well as biomarker detection. The principle of the method is an analysis of 
stained cells in suspension passing by an electron detection apparatus in a stream of fluid 
(248).  
 
To investigate the platelet function in whole blood and PMPs from platelets rich plasma 
(PRP), flow cytometry was used. Briefly, the samples, either whole blood or PMP were 
labeled with antibodies recognizing platelets and platelet activation markers (P-selectin and 
CD40L).  
 
Platelets and PMPs were defined by their size characteristics and antibody recognition. In 
addition, platelet aggregation was measured by flow cytometry-based platelet aggregation 
assay (FCA) using a modified protocol (249).  In short, whole blood was divided into two 
mPGES-1 -/-
mPGES-1 +/+
mPGES-1 -/-
mPGES-1 +/+
LPS
24 hours
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and liver was 
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equal portions; each portion was labeled with different antibodies. After the incubation for 
15 minutes’, the portions were combined and incubated additionally for 15 minutes. 
Platelets were then activated by incubation with adenosine diphosphate (ADP) by shaking 
for 10 minutes.  Cell fixation was performed before the analysis by flow cytometry (Figure 
5).  
 
 
 
 
Figure 5 | The illustration of the flow cytometry procedure. 
Whole blood or platelet rich plasma (PRP) was labeled with fluorescent antibodies. The suspended sample 
was run using flow cytometry. The cell suspension gets focused by fluid and causing cells to pass through a 
laser beam, one cell at the time. Fluorescence emitted from stained cells as well as forward and side scattered 
light is detected.  
 
 
The main advantage utilizing this method is the ability to characterize antigen expression 
on a cell-by-cell basis in the large heterogeneous population of cells.  
 
This method was used in Paper II to measure the platelets PMPs levels, the platelet-
leukocyte aggregates and platelet aggregation. 
 
 
Immunohistochemistry (IHC) 
 
IHC was used to detect the presence of certain cells as well as to study any alterations after 
treatment with GC at cellular and protein levels in cross-sectional muscle tissue from 
patients (250, 251).  
 
Briefly, sections were rehydrated with phosphate-buffered saline (PBS). As a 
permeabilizing detergent, the saponin was used; the addition of the saponin is important 
when staining of intracellular markers. Before the application of primary antibody, the 
endogenous peroxidase activity was blocked by incubation with hydrogen peroxide (H2O2) 
in the dark. The blocking is important in order to avoid non-specific background since 
many cells and tissues contain endogenous peroxidases.  
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The tissue was then blocked with the serum from the same species as the studied tissue, 
before and during the application of primary antibody. The avidin-biotin blocking solution 
was applied to reduce the non-specific background since many cells contain endogenous 
biotin. Avidin, a large glycoprotein, has a very high affinity for biotin, a low molecular 
weight vitamin, which can be conjugated to antibodies and other biological molecules. 
Also, before incubation with the biotinylated secondary antibody, the tissue was blocked 
with serum from the same species origin as the secondary antibody.  
 
Incubation with avidin-biotin-peroxidase complex (ABC) was done. The ABC technique 
comprises of three steps, at the first step, an unlabeled primary antibody is added, at the 
second step, the biotinylated secondary antibody is added and at the third step, the complex 
of avidin-biotin-peroxidase is applied. The peroxidase then converts a substrate to different 
colored end products. In our experiments, the 3,3'-diaminobenzidine (DAB) was used as the 
substrate to develop the reaction. Mayer’s Hematoxylin was used to counterstain the tissue 
and to make the nuclei of cells visible. As the final step slides were mounted in glycerol for 
observation by microscope (Figure 6).  
 
 
Figure 6 | Schematic overview 
of the IHC procedure.  
An antigen on the cell surface 
was recognized by the primary 
antibody. The HRP conjugated 
secondary antibody binds to the 
primary antibody. DAB was 
used as a substrate to visualize 
the binding of the antibodies.  
 
 
 
 
The main advantage of this method is that it provides the qualitative description and semi-
quantitative scoring of the protein pattern in the tissue. Although incorrect freezing, storing 
and sectioning of biopsies could cause artifacts. 
 
This method was used in Paper IV to detect the presence of immune cells as well as to 
study alteration in the protein expression after treatment with GC at the cellular level in 
muscle tissue from PM and DM patients. 
 
 
Solid-phase extraction (SPE) 
 
SPE is suitable to separate analytes of importance (252) from a wide selection of material, 
such as urine, water, blood, soil and animal tissue homogenate (253). In brief, the filter 
cartridge was equilibrated with methanol, which is a slightly polar solvent, although a more 
non-polar solvent can also be used. As a result, the surface gets wet, and the solvent 
Fixed cell/tissue
Antigen recognition 
Conjugated secondary antibody
Primary antibody
Brown precipitate
HRP
DAB
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penetrates the polymer in the column making it assessable to the samples. The samples 
were spiked with internal standards and were loaded onto the column and washed trough 
the stationary phase.  
The analytes that have polar properties interact and maintain on the polar sorbent, other 
non-polar impurities pass through the column. A washing solution containing slightly polar 
or non-polar solvent, was added to remove further impurities. The molecules bound to the 
column were then eluted by adding the polar solvent with the proper pH. With this 
technique, the hydrophobic material in hydrophilic solvents sticks to the column and the 
hydrophilic material runs through.  
 
The main advantages of this method are the high accuracy and no risk for cross-
contamination, also the sample handling is easy due to fewer process steps (254).  
 
This method was used in Paper I to measure the prostanoid production by WT mPGES-1 
and variants incubated with PGH2. 
 
 
Liquid-liquid extraction (LLE) 
 
LLE is a technique used to disperse compounds based on their solubility in two different 
liquids such as water and an organic solvent (255, 256). Briefly, samples were thawed in 
the refrigerator and centrifuged. Internal standards were added to each sample together with 
a mixture of methanol and chloroform (2:1). The samples were then vortexed and 
sonicated. The organic phase, containing lipids, was removed and saved in Eppendorf 
tubes. The samples were then re-extracted by the same procedures as described above. The 
samples containing lipids were combined and evaporated to increase the concentration of 
lipids in the extraction solvent.  
 
LLE extractions offer many analytical benefits; the primary advantage is the ability to 
operate in a continuous, multistage countercurrent mode, giving rise to a very efficient 
separation. One disadvantage is that the method is time-consuming when extract needs to 
be enriched, and multiple extractions are necessary.  
 
This method was used in Paper V to measure lipids and FA in serum from myositis 
patients.  
 
 
Statistical analyses 
 
In Paper I, unpaired t-test was used to analyze data. P<0.05 was considered to be 
statistically significant Data are expressed as the mean ± SD. 
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In Paper II, to obtain a normal distribution data were log transformed before statistical 
analysis. WT and KO mice were compared using the unpaired Student’s t-test. P values less 
than 0.05 were considered to be statistically significant. Prism 6.0 software (GraphPad 
software, USA) was used for statistical analysis. Data are expressed as the mean ± S.E.M. 
 
In Paper III, where duplicate measurements of tissue from the same animals were made 
the values were averaged and considered as n=1. Data were compared using Student’s 
unpaired t-test, one sample t-test, one-way or two-way ANOVA with Dunnett’s posthoc 
test as indicated in individual figure legends. The level of significance was set at a P≤ 0.05. 
Data were analyzed using Prism 6.0 software (GraphPad software, USA). Data are 
expressed as the mean ± standard error. 
 
In Paper IV, Wilcoxon signed rank test was used for analysis of clinical and experimental 
values. P values less than 0.05 were considered to be statistically significant. Data are 
expressed as the mean ± SD. 
 
In Paper V, Mann-Whitney’s U test and Wilcoxon’s signed rank test was used to analyze 
data. The Spearman rank correlation test was used to evaluate the correlation between the 
clinical parameters and the levels of specific lipid species or FA in serum. Data are 
expressed as the mean ± SD, differences were considered significant if P<0.05. 
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RESULTS AND DISCUSSION 
This thesis comprises five different studies regarding the functions and effects of PGE2 as 
well as other lipids in rheumatic diseases. The results of three studies have been published, 
and the publications can be found at the end of this thesis as paper I, paper II and paper 
IV. Two studies including paper III and paper V have not yet been published and are 
available in the form of manuscripts. In this section the main findings are presented and 
discussed in the context of the current literature.  
 
Essential residues for the catalytic function of mPGES-1  
This section will focus on the catalytic function of mPGES-1. 
 
 
Determination of the catalytic mechanism of mPGES-1 activity by site-
directed mutagenesis (Paper I) 
 
In Paper I, we extended our studies of mPGES-1 activity to examine and clarify which 
residues are important for the catalytic function of mPGES-1. There are two main reasons 
why it is important to study the catalytic function of mPGES-1. Firstly, it would provide 
new information for characterization and mapping of the catalytic mechanisms of MAPEG 
superfamily members. Secondly and more importantly, knowing the exact catalytic 
function of the enzyme would help in drug development of mPGES-1 inhibitors that will be 
used as future anti-inflammatory drugs.  
 
Several catalytic mechanisms have been proposed for mPGES-1 (146-148). Based on these 
findings regarding predictions and structural studies, we aimed to investigate the role of the 
amino acid residues Asp49, Arg73, Arg126 and Ser127 in the catalytic function of mPGES-
1, all in close vicinity of the GSH molecule. The variants of mPGES-1 with substituted 
amino acids were obtained by site-directed mutagenesis. The mutated enzyme variants were 
then cloned and expressed in both the E. coli and the Baculovirus expression systems. Their 
catalytic significance was evaluated by activity measurements with prostanoid profiling by 
liquid-chromatography tandem mass spectrometer LC-MS.  
 
We have found that all constructs expressed mPGES-1 to varying degrees and that only WT 
mPGES-1, Arg73 and Ser127 variants catalyzed the formation of PGE2 at a significant level 
compared to their negative controls consisting of denatured by boiling protein. All other 
quantified prostanoids were produced at background level in our E. coli system. Our 
measurements are in the range with the initially observed specific activity of purified 
mPGES-1 (257).  
 
Previous structural data suggested that Ser127 might be important residue for the catalytic 
function of mPGES-1 (146). However, our results demonstrate that mutation of Ser127 to 
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alanine (Ala) only lowers the activity of the enzyme, measured in E. coli membranes. It has 
been some inconsistency with obtaining similar data when using different expression 
systems that might influence the activity of the enzyme. Therefore, we decided to use a 
second expression system, Baculovirus expression system. In addition, the activity of 
Ser127 cysteine (Cys) variant from SF9 cells was measured by glutathione transferase 
(GST) activity assay and quantified by PGH2 isomerization and showed only lowered 
activity compared to WT mPGES-1. Thus, regardless of the assay employed, the Ser127Ala 
variant retained activity. We concluded that Ser127 residue is not important for the catalytic 
activity, which are in line with recent findings by Brock et al. (147).  
 
Furthermore, we have also demonstrated that mutations of Asp49 to Ala and Arg126 to 
either Ala or leucine (Leu) in membrane fractions from the E. coli expression system 
resulted in complete loss of activity confirming a central role of these residues in the 
catalytic function of mPGES-1. Interestingly, no formation of PGF2α was detected, which is 
contradictory to previous observations (147, 148).  
 
In summary, we propose two alternative chemical reactions for the mPGES-1 catalyzed 
PGE2 synthesis mechanism (Figure 7A). The first proposition is that an attack of the GSH 
thiolate on C9 oxygen occurs, forming a sulfenic acid ester, followed by a proton receiving 
at C11 and proton abstraction at C9 by Asp49. Arg126 is thought to stabilize the leaving 
GSH thiolate, leading to the PGE2 formation. The second proposition is that Asp49 initiates 
the reaction by abstracting a proton at C9, splitting the protonated GSH and donating a 
proton instead, leading to the formation of PGE2 (Figure 7B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 | Suggested mechanism of PGH2 isomerization to PGE2 by the active site of mPGES-1. 
A) The thiol of glutathione (GSH) gets activated followed by a proton donation from PGH2 via Asp49. Asp49 
abstracts then the proton from where a carbonyl forms as the oxygen sulfur bond is broken. The leaving GSH 
thiolate is stabilized by Arg126. B) The thiol of GSH gets activated followed by proton donation via the GSH 
thiol to Asp49 that forms a complex with Arg126. Both suggested reactions result in the formation of the 
product PGE2 (149).  
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To conclude, in Paper I we showed that Arg126 and Asp49 are absolutely required for the 
catalytic activity of mPGES-1 while Ser127 and Arg73 do not seem to be central to the 
catalytic mechanism of the enzyme. These findings have important implications with regard 
to the development of novel mPGES-1 inhibitors. Our results are important since clarifying 
the catalytic mechanisms of mPGES-1 will help to structure-based design and development 
of mPGES-1 inhibitors. 
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Role of mPGES-1 inhibition in inflammation and cardiovascular 
safety 
This section will focus on the beneficial role of mPGES-1 inhibition in cardiovascular 
safety.  
 
 
mPGES-1 deletion affects platelet functions (Paper II) 
 
In Paper II, we aimed to examine the effect of genetic deletion of mPGES-1 regarding 
platelet number and activation in normal and inflammatory conditions. mPGES-1 is 
involved in the pathogenesis of RA promoting inflammatory processes via multiple 
mechanisms, however, its role in platelet functions has not been studied so far.  Recently, 
activated platelets were recognized as one of the major players in RA (258, 259) linking 
active synovitis, systemic inflammation and cardiovascular manifestations in RA patients.  
 
Dovizio and coworkers (201) demonstrated that mPGES-1 is not expressed in human 
platelets. In line with their observation, we have shown that murine platelets do not either 
express mPGES-1 (186), but they are known to express EP receptors (183, 202). 
Consequently, genetic deletion of mPGES-1 via attenuating the induced PGE2 production 
may potentially regulate functions of platelets. Indeed, we showed a reduced platelet 
number in whole blood from WT mice treated with LPS compared to that from KO mice. 
This reduction in platelets number could be due to the LPS-induced activation of platelets 
followed by consumption of the platelets, most likely by attaching to cells/endothelium or 
by accumulation in the liver or lungs (186, 260, 261).  
 
Furthermore, the expression of platelet activation markers, P-selectin and CD40L, were 
stronger in WT mice treated with LPS compared to KO mice (Figure 8). CD40L modulates 
inflammatory immune responses by binding to its cognate receptor CD40 expressed on 
neutrophils (262). Reducing platelet activation will subsequently lead to impaired activation 
of neutrophils and reduced inflammation. Further,  the levels of soluble P-selectin and 
CD40L in plasma of RA patients is found to correlate with disease activity (195). Thus, 
lower levels of P-selectin and CD40L in KO mice might indicate less inflammation. 
 
Moreover, mPGES-1 deletion significantly reduced the formation of platelet–leukocyte 
aggregates and platelet aggregation in mice after LPS stimulation (Figure 8). This finding is 
in line with the results from another study demonstrating that a low concentration of PGE2 
enhances platelet aggregation in mice and that activation of EP3 is sufficient to mediate the 
pro-aggregatory actions of low levels of PGE2 (102). The release of PMP was also 
significantly lower in response to LPS stimulation in KO mice compared with WT mice. 
Activated platelets are known to release PMPs, an important player in cell communications 
(196) and an essential pro-inflammatory factor in the pathogenesis of RA (193-195). The 
decreased PMP levels would reflect reduced activation of platelets and consequently the 
lower degree of inflammation.  
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Figure 8 | Platelet activation in WT and mPGES-1 KO mice. 
Platelet activation was assessed by (A) CD62P expression, (B) CD154 expression, (C) platelet–leukocyte 
aggregates and (D) PMP counts. Samples were obtained from WT and mPGES-1 KO mice treated with or 
without LPS for 24 hours. The horizontal line in the boxes represents the median. *p<0.05, **p<0.01, 
***p<0.00, ns, not significant (186). 
 
 
In addition, platelet accumulation and tendency to aggregate using immunofluorescent 
CD41 and fibrinogen staining were examined in livers from WT and KO mice stimulated 
with LPS for 24 hours. No changes were seen in the CD41 expression in WT mice 
compared to KO.  Fibrinogen staining was detected in vessels, moreover, a trend towards 
less fibrinogen staining in the vessels of KO mice was observed. The percentage of total 
vessel area was significantly lower in KO mice compared to WT mice, indicating less 
inflammation.  
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Figure 9 | Schematic overview of platelet activation in WT and mPGES-1 KO mice. 
The expression of platelet activation markers CD62P and CD154, the release of platelet-derived 
microparticles (PMP), as well as the platelet binding to leukocytes were significantly reduced in mPGES-1 
KO mice compared to WT in inflammatory condition. 
 
 
In summary, we demonstrated that systemic lack of mPGES-1 decreased platelet activation, 
PMP formation, platelet binding to leukocytes and reduced platelet aggregation in settings 
of inflammation. These results imply that pharmacological inhibition of mPGES-1 might be 
beneficial regarding both inflammation and the cardiovascular safety which is essential for 
the development of novel mPGES-1 inhibitors (Figure 9). 
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Beneficial effects on the cardiovascular and renal system by mPGES-1 
deletion compared to COX-2 inhibitors (Paper III) 
 
In order to estimate the relative cardiovascular safety of mPGES-1 as a therapeutic target, 
in Paper III we aimed to investigate how mPGES-1 and PGIS in comparison with COX-2 
influence the vascular as well as the renal pathway associated with ADMA and eNOS. For 
this purpose, we have utilized mPGES-1 and PGIS deleted mice.  
 
First, we measured prostaglandins generation in circulation, in the plasma, and in isolated 
blood vessel ex vivo. In the freshly isolated aorta from WT mice, ten times higher formation 
of PGI2 was detected compared to PGE2. mPGES-1 deletion led to reduced release of PGE2 
in the freshly isolated aorta, suggesting that mPGES-1 is constitutively expressed in large 
vessels where it contributes to physiological PGE2 production. In plasma, the levels of 
PGE2 were five times higher than the levels of PGI2. Interestingly, the levels of plasma PGI2 
were elevated in KO mice, suggesting that at some sites of the body, the shunting of PGH2 
to PGIS occurs.  
 
We also demonstrated that COX-2 is highly expressed in the renal medulla where it acts as 
a key regulator of the genes controlling the formation of the endogenous eNOS inhibitor 
ADMA. (211). mPGES-1, on the other hand was mostly expressed in renal cortex. 
 
COX-2 inhibition with parecoxib increased the expression of genes responsible for ADMA 
synthesis while reducing expression of genes responsible for the degradation. 
Consequently, the ADMA levels were elevated in plasma of mice treated with parecoxib. In 
contracts, mPGES-1 deletion did not affect these genes related to ADMA production and 
degradation and subsequently did not affect the ADMA levels in plasma. These 
observations suggest that targeting mPGES-1 instead of COX-2 would spare this renal 
function. These data are also in line with the results of another study suggesting that 
mPGES-1 is not the major regulator of blood pressure and salt/water handling in the kidney 
(263).  
 
In order to address whether PGI2 signaling contributes to the renal pathway, the levels of 
ADMA and creatinine were measured in PGIS deleted mice. Both parameters were 
increased to the similar degree as seen in mice treated with parecoxib, signifying that PGI2 
and not PGE2 is the major prostaglandin regulating renal functions including ADMA 
metabolism.  
 
Finally, we examined the effect of mPGES-1 deletion on eNOS depended vasodilator 
response induced by acetylcholine and found that mPGES-1 deletion significantly enhanced 
the eNOS driven dilator response to acetylcholine in the aorta.  
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Figure 10 | Schematic overview of findings and hypothesis. 
The inhibition of mPGES-1 could potentially be cardioprotective and these properties are hypothesized to be 
due to the retained anti-inflammatory and anti-cancer benefits of NSAIDs (COX-2 inhibitor) while avoiding 
the renal and cardiovascular PGI2/ADMA axis. 
 
In summary, the PGIS but not mPGES-1 retains the cardiovascular protective functions of 
COX-2 on the renal ADMA pathway. These data provide interesting evidence for the 
development of selective inhibitors of mPGES-1 as safer alternatives to NSAIDs for 
treating inflammation, pain, and cancer (Figure 10).  
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The role of lipid mediators in the pathogenesis of IIM 
This section will focus on lipid mediators involved in the pathogenesis of myositis.  
 
 
Effects of conventional immunosuppressive treatment on molecular 
mechanisms in muscle from adult patients with PM or DM (Paper IV) 
 
In paper IV, we aimed to elucidate further the molecular events contributing to the 
unrelenting compromised muscle function despite conventional immunosuppressive 
treatment in myositis patients by utilizing gene expression profiling. This approach gives us 
the possibility to identify new molecular mechanisms involved in the pathogenesis of 
myositis and treatment response in patients. We have studied global gene expression 
profiles in muscle biopsies from six patients before and after immunosuppressive treatment. 
 
We observed a significant downregulation of genes related to immune response and 
inflammation such as MHC class I and II, co-stimulatory molecules, chemokines and 
cytokines, after treatment with GC. Furthermore, we showed the suppression of genes 
involved in the IFN pathway after treatment (226). Previous studies have shown the 
overexpression of the IFN-inducible genes in whole blood from myositis patients which 
correlated with disease activity and was reduced after immunomodulatory therapies (264, 
265). Type I IFN signature genes are expressed at high levels at baseline in the skeletal 
muscle of myositis patients, this is thought to be a predictor of the response to rituximab in 
PM and DM, where higher expression of the IFN-inducible genes is associated with a 
greater response (266). Our novel finding demonstrates that the IFN-inducible genes are 
expressed in the muscle tissue from patients and are downregulated by immunosuppressive 
treatment, most likely reducing inflammation in the muscle tissue. Thus, our findings have 
provided further insight into the mechanisms of the beneficial outcomes of conventional 
immunosuppressive treatment in patients with PM or DM.  
 
Our group has previously demonstrated a persisting expression of mPGES-1, COX-2, and 
5-LO in muscle tissue from PM or DM patients despite treatment leading to the production 
of pro-inflammatory lipids PGE2 and LTB4 (20, 21). In line with our previous findings, we 
could not detect any changes in the expression of these enzymes or alterations at the protein 
level of EP3, EP4, and CysLTR1 receptors in response to treatment. This persisting 
expression of pro-inflammatory enzymes and lipid mediators might contribute to the 
chronic inflammation and muscle weakness associated with myositis.  
 
Moreover, genes associated with muscle tissue remodeling were altered after treatment, 
suggesting protein breakdown and delayed muscle regeneration, consequently affecting 
muscle growth. The expression of FK506 binding protein 5 (FKBP5) gene, implicated in 
muscle tissue remodeling, was upregulated after the immunosuppressive treatment. The 
expression of FKBP5 was further validated by western blot where an increase of the 
expression of the protein was detectable after treatment, suggesting a negative effect on 
muscle tissue remodeling and growth. Moreover, we detected increased expression levels of 
myostatin, suggesting inhibition of myogenesis and a negative effect on muscle growth. 
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Also, the expression of Ras-related associated with diabetes (RRAD) gene and myosin 
binding protein H (MYBPH) gene were both downregulated after treatment; this could be a 
sign of reduced muscle regeneration.  
 
In addition, myosin, heavy polypeptide 4 (MYH4) and alpha-actinin-3 (ACTN3) genes, 
related to fast type II muscle fibers, were both upregulated after treatment. Furthermore, 
this finding was verified by the analysis of the fiber-type composition where a switch 
towards type II muscle fibers in response to treatment was observed (Figure 11). Our results 
are in agreement with previous studies where they have reported a shift towards the fast-
twitch type II muscle fibers in myositis patients, which might be restored by exercise (267, 
268).   
 
 
 
Figure 11 | The fiber type composition before and after treatment in PM and DM patients. 
(A) The percentage of type I muscle fibers was significantly decreased after glucocorticoid treatment from 
median 52 % to median 43 % (*p <0.05). (B) The proportion of type II fibers was significantly increased after 
treatment from median 48 % to median 57 % (*p <0.05) (226). 
 
 
The most striking finding was that the expression of a number of genes involved in lipid 
and FA metabolism, lipid uptake, and lipid accumulation was changed after 
immunosuppressive treatment, signifying a probable lipotoxic effect on muscles. We 
detected the upregulated expression of ceramide synthase 3 (CERS3) gene, suggesting an 
increased accumulation of ceramide which has previously been linked to insulin resistance 
(269). Additionally, ceramides have been associated with skeletal dysfunction and fatigue 
in chronic inflammatory conditions (270). The altered expression of the genes related to 
lipid metabolism suggests deregulated intramuscular lipid storage that might lead to skeletal 
muscle dysfunction. 
 
In conclusion, we have revealed that the anti-inflammatory effect of conventional 
immunosuppressive treatment was combined with the negative impact on genes involved in 
muscle tissue remodeling and lipid metabolism, at least partly underlying the persistent 
muscle weakness and fatigue often observed in patients despite treatment.  
0
20
40
60
80
100
Type I before Type I after 
Fi
be
r t
yp
e %
0
20
40
60
80
100
Type II before Type II after
Fi
be
r t
yp
e %
* 
* 
A B 
 49 
Serum lipids and FA profiles are altered in patients with PM or 
DM (Paper V) 
 
Changes in the expression of genes related to lipid and FA metabolism that we detected in 
the patients with PM or DM after treatment (Paper IV) might lead to altered lipid and FA 
profiles. Multiple studies demonstrated that skeletal muscle FA profiles could affect muscle 
growth, functions and inflammation (54, 84, 85, 87). To clarify lipid/FA involvement in the 
pathogenesis of IIM, we aimed to evaluate the lipid and FA-profiles in serum from patients 
with PM or DM in comparison to healthy individuals and in response to 
immunosuppressive treatment utilizing gas chromatography (GC-MS) and LC-MS/MS.   
 
We detected, that the FA composition of total serum lipids was altered in PM and DM 
patients compared to healthy individuals. The levels of palmitic (16:0) acid in serum were 
significantly higher in myositis patients compared to healthy individuals. Several studies 
have suggested that palmitate has pro-inflammatory properties inducing inflammation and 
atrophy in myotube in vitro (271). Moreover, the levels of AA were significantly lower in 
myositis patients in comparison to healthy individuals. The low AA levels are most likely 
due to the conversion of AA to pro-inflammatory eicosanoids by COX and 5-LO; both 
enzymes are upregulated in PM and DM patients (20, 21). Furthermore, the FA 
composition of serum lipid classes confirmed that the levels of the PC species comprising 
PUFA were lower while the levels of the PC and triglycerides (TG) species containing SFA 
and monounsaturated FA (MUFA) were higher in myositis patients compared to healthy 
individuals. Our results are in line with the previous reports that RA patients have lower 
levels of PUFAs and higher levels of SFA in the serum PC, erythrocytes, and adipose tissue 
compared with healthy controls (53, 221). 
 
The role of GC in the dysregulation of lipid metabolism in skeletal muscle has recently 
been described (226, 272). In myotubes from mice in vitro and skeletal muscle ex vivo, GC 
usage impacted the expression of genes involved in lipid storage, mobilization, and 
utilization (272). Moreover, our study revealed that in myositis patients, GC treatment 
affected the expression of genes involved in lipid and FA metabolism in skeletal muscle 
(226) which possibly could lead to changed lipid and FA profiles in those patients. In line 
with these findings, we could detect increased levels of EDA and EPA in myositis patients 
after immunosuppressive treatment. EDA have been shown to exert anti-inflammatory 
effects, affecting PGE2 and nitric oxide (NO) pathways (273). EPA, on the other hand, 
gives rise to metabolites that are less inflammatory than those produced from AA as well as 
reduces production of cytokines (82). This data indicates that increased serum EPA and 
EDA levels after treatment might have a beneficial anti-inflammatory effect. 
 
In addition, changes in serum PC, PE and LPC profiles in myositis patients after treatment 
was observed. Remarkably, the same lipid species such as (32:1), (34:3), (36:6) and (36:5) 
were upregulated within both PC and PE, whereas (38:4) and (40:6) were lower after the 
immunosuppressive treatment. Furthermore, we observed increased levels of LPC(16:1) 
and LPC(20:5) after treatment. Nevertheless, we did not detect a clearly defined pattern in 
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the changes of PUFA or SFA-enriched lipid species in response to the immunosuppressive 
treatment. 
 
Also, a significant positive correlation (rs=0.821) was observed between a muscle 
performance index and the levels of PC(38:4) in serum from patients after 
immunosuppressive treatment, that might reflect lipid and FA metabolism deregulation in 
PM and DM patients contributing to muscle fatigue and impairment. 
 
 
Figure 12 | Schematic overview of findings. 
FA composition of total serum lipids and lipid classes are altered in myositis patients compared to healthy 
individuals and in relation to immunosuppressive treatment. However, no clearly defined pattern in the 
changes of PUFA or SFA-enriched lipid species in response to the immunosuppressive treatment was 
detected. 
 
 
In conclusion, we have found that FA composition of total serum lipids and lipid classes are 
significantly altered in PM and DM patients compared to healthy individuals and in relation 
to immunosuppressive treatment (Figure 12). These results imply that FA metabolism 
might be dysregulated in PM and DM patients and further affected by the treatment 
contributing to muscle weakness and damage. 
 
 
 
 
Healthy individualsMyositis patients
Before After
Immunosuppressive treatment
EDA
EPA
Serum
PUFA 
SFA
MUFA
Palmitic acid
Arachidonic acid
Serum
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FA metabolism might be dysregulated in myositis patients and further affected by the 
immunosuppressive treatment contributing to muscle weakness and damage. 
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CONCLUSIONS AND FUTURE PERSPECTIVES 
This thesis has contributed to a better understanding of the involvement of lipid mediators 
in chronic autoimmune diseases such as RA and IIM. We have provided new knowledge on 
the catalytic mechanism and the impact of mPGES-1 on inflammation and cardiovascular 
safety. Furthermore, we have demonstrated that lipid metabolism is altered in myositis 
patients and might contribute to disease pathogenesis. 
 
There have been many attempts to clarify the catalytic mechanism of the mPGES-1 
enzyme, however, with somewhat controversial results. To understand the mechanism and 
identify the critical residues for the mPGES-1 function is of great value when it comes to 
the development of a new generation of selective NSAIDs. In Paper I, we have shown that 
the residues Arg126 and Asp49 are essential for the catalytic activity of mPGES-1. We also 
demonstrated that residues Ser127 and Arg73 are not central to the catalytic mechanism. 
Further investigations facilitating site-directed mutagenesis and steady state kinetics are 
important to clarify the most important residues for the catalytic function of mPGES-1. 
This will lead to better understanding of the exact reaction mechanism of mPGES-1 and 
will be beneficial for the development of new mPGES-1 inhibitors, for instance by 
synthesizing transition state inhibitors. Future experiments including co-crystallization of 
the protein with the inhibitor would provide important information regards to the location 
of the inhibitor binding site as well as the orientation of the inhibitor within the enzyme.  
 
Although deletion or pharmacological suppression of mPGES-1 leads to suppression of 
inflammation via multiple mechanisms, more studies are required to elucidate the impact of 
mPGES-1 inhibition on different pathological and physiological processes. In Paper II, we 
have investigated whether mPGES-1 deletion might be beneficial for reducing 
inflammation via the suppression of platelet functions. We have demonstrated that systemic 
deletion of mPGES-1 prevented platelet activation, PMP release, the formation of platelet-
leukocyte aggregates and reduced platelet aggregation in inflammatory conditions. These 
effects can also contribute to the cardiovascular safety of mPGES-1 inhibitors. In line, the 
results presented in Paper III further confirmed the cardioprotective effects of mPGES-1 
deletion. We have demonstrated that the cardiovascular protective functions of COX-2 on 
the plasma ADMA and vascular eNOS are not mediated by mPGES-1. These data provide 
better confidence in the development of selective inhibitors of mPGES-1 as a safer 
alternative to NSAIDs for anti-inflammatory treatment of chronic autoimmune diseases.  
Further investigations will clarify the cardiovascular safety properties of mPGES-1 
inhibitors. Several mPGES-1 inhibitors have become available for research use; this 
provides with an exceptional opportunity to characterize the beneficial and potential side 
effects of the inhibitors both in vitro studies as well as in vivo animal studies utilizing 
different disease models. The characterization of mPGES-1 inhibitors could provide 
information regarding the importance of mPGES-1 derived PGE2 in acute and chronic 
inflammation as well as in cancer. The challenge by inhibiting mPGES-1 activity is to keep 
the balance between damaging and protective PGE2 effects. Moreover, it would be of great 
therapeutic value to elucidate whether mPGES-1 inhibitors in combination with anti-
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rheumatic drugs such as GC and DMARDs would provide the benefits in controlling 
synovial inflammation. 
 
In Paper IV, we have studied effects of GC treatment on gene expression profiles in 
muscle tissue from myositis patients. We have found that the beneficial anti-inflammatory 
effect of treatment was combined with the negative impact on genes involved in muscle 
tissue remodeling and lipid metabolism. These results suggest that deregulation of muscle 
lipid and FA metabolism may contribute to sustained muscle impairment seen in myositis 
patients despite immunosuppressive therapy. Future studies will elucidate the molecular 
mechanisms involved in disease pathogenesis. Deeper analysis by validating the global 
gene expression data will help to determine important genes affected by the GC treatment 
that could potentially be used as biomarkers for treatment response in myositis patients. 
 
To validate the observed changes in lipid metabolism in myositis patients, in Paper V, we 
have analyzed the serum FA and lipid profiles. We have found that FA composition of total 
serum lipids and lipid classes are significantly altered in myositis patients compared to 
healthy individuals and in response to immunosuppressive treatment. These results imply 
that indeed, FA/lipid metabolism is dysregulated in myositis patients and further affected 
by the treatment possibly contributing to muscle weakness and damage.  
Future investigations will clarify if the changes in serum FA composition indeed reflect the 
FA composition in the muscle tissue and if they may be used as predictive markers for 
patients with myositis. It would also be interesting to investigate whether FA and lipid 
profiles might be improved in myositis patients in response to exercise or by dietary 
supplements.  
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